

Human Medicines Regulations 2012

Advisory Bodies

Commission on Human Medicines

Annual Report 2024

Published July 2025



Medicines and Healthcare products Regulatory Agency

**HUMAN MEDICINES REGULATIONS 2012
ADVISORY BODIES**

Commission on Human Medicines

**ANNUAL REPORT
2024**

**Laid before Parliament pursuant to
Part 2, Regulation 12(4) of
the Human Medicines Regulations 2012**



© Crown copyright 2025

Published by the Medicines and Healthcare products Regulatory Agency

This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3.

Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.

This publication is available at <https://www.gov.uk/mhra>

Any enquiries regarding this publication should be sent to the Medicines and Healthcare products Regulatory Agency at:

Medicines and Healthcare products Regulatory Agency

Customer Services

10 South Colonnade

Canary Wharf

London E14 4PU

Tel: 020 3080 6000

E-mail: info@mhra.gov.uk

ISBN 978-1-8384147-4-0

Printed on paper containing 40% recycled fibre content minimum

Printed in the UK by HH Associates Ltd. on behalf of the Controller of His Majesty's Stationery Office

Table of Contents

Foreword by the Minister of State for Health	7
Commission on Human Medicines	8
Annual Report - 2024	9
About the Commission on Human Medicines	9
Chair's perspective on the year - Professor Sir Munir Pirmohamed	10
New active substances	10
Medicines that address unmet clinical need	11
Post-pandemic COVID vaccines	11
Extension of use of approved medicines	12
The Early Access to Medicines Scheme (EAMS)	13
Orphan designations	13
Reclassification of medicines	13
Advice on Established/Generic medicines	14
Policy/Strategy Advice	14
Advice to Secretary of State for Health and Social care	16
Backlog Clearance	16
Safety of Medicines	17
Involving patients' views at the CHM	17
Highlights of our 2024 achievements	19
Breakdown of advice provided by the Commission on Human Medicines, Expert Advisory Groups (EAG), Expert Working Groups (EWG) in 2024	20
Membership	20
Costs	21
Code of Practice for the Commission on Human Medicines and other expert advisory committees	22
Membership of the Commission on Human Medicines (CHM)	23
CHM Co-opted Members, Invited Experts and Observers	25
Membership of the Cardiovascular, Diabetes, Renal, Respiratory & Allergy Expert Advisory Group (CDRRA EAG)	29
Membership of the Chemistry, Pharmacy and Standards Expert Advisory Group (CPSEAG) ...	31
Membership of the Clinical Trials, Biologicals & Vaccines Expert Advisory Group (CTBVEAG)	33
Membership of the Gastroenterology, Rheumatology, Immunology & Dermatology Expert Advisory Group (GRIDEAG)	34
Membership of the Infection Expert Advisory Group (IEAG)	35
Membership of the Medicines for Women's Health Expert Advisory Group (MWHEAG)	36
Membership of the Neurology, Pain & Psychiatry Expert Advisory Group (NPPEAG)	38
Membership of the Oncology & Haematology Expert Advisory Group (OHEAG)	39

Membership of the Paediatric Medicines Expert Advisory Group (PMEAG)	40
Membership of the Pharmacovigilance Expert Advisory Group (PEAG)	42
Membership of the Antidepressant Risk Minimisation Expert Working Group (ARMEWG)	44
Membership of the CHM's Highly Personalised Medicines Expert Working Group (HPMEWG, formerly Cancer Vaccines EWG).....	46
Membership the Real World Data Expert Working Group (RWD EWG).....	49
Membership of the Valproate Epigenetics Expert Working Group (VEEWG).....	50
Membership of the CHM's Valproate Implementation Working Group (VIEWG).....	51
ANNEX A - DECLARATION OF INTERESTS	53

Foreword by the Minister of State for Health

It gives me great pleasure to present the annual reports for 2024 of the Human Medicines Regulations Advisory Bodies: The Commission on Human Medicines. These reports include a record of members' interests in the relevant industry as per the Conflicts of Interest Code of Practice.

On behalf of all Health Ministers, I would like to thank the Chairs and Members of the Commission and all those who contribute to their many Expert Advisory Groups and Expert Working Groups whose professional expertise, commitment and hard work plays a vital role in ensuring that the medicinal products we take continue to meet the highest standards of safety, quality and efficacy.

Karin Smyth MP

Commission on Human Medicines

Annual Report - 2024

About the Commission on Human Medicines

The Commission on Human Medicines (CHM) is an advisory non-departmental public body, sponsored by the [Department of Health and Social Care](#) (DHSC). The CHM was established in 2005 to advise ministers and the Licensing Authority, [Medicines and Healthcare products Regulatory Agency](#) (MHRA), on the safety, efficacy and quality of medicinal products.

The functions of the CHM are set out in Regulation 10 of the Human Medicines Regulations 2012 (SI 2012/1916). This report presents a summary of the work undertaken by CHM in 2024.

The functions of the CHM are:

- to advise the Health Ministers and the Licensing Authority (LA) on matters relating to human medicinal products including giving advice in relation to the safety, quality and efficacy of human medicinal products where either the Commission thinks it appropriate or where it is asked to do so;
- to consider those applications where the LA has a statutory duty to refer to the CHM or chooses to do so;
- to consider representations made (either in writing or at a hearing) by an applicant or by a licence or marketing authorisation holder in certain circumstances;
- to promote the collection and investigation of information relating to adverse reactions to human medicines for the purposes of enabling such advice to be given.

Chair's perspective on the year - Professor Sir Munir Pirmohamed

The CHM depends heavily on the dedication, knowledge and experience of its experts and the considerable efforts from all experts, including lay representatives and invited patient experts, are greatly appreciated and valued. The immense contribution of the CHM's experts has ensured advice to the MHRA and the Health Ministers is based on rigorous examination of scientific data leading to regulatory decisions translated effectively into clinical practice, with a direct benefit to patients.

New active substances

In 2024, the CHM continued to carefully consider the data on quality, efficacy & safety of a number of new active substances and after detailed deliberations, advised the MHRA on the approvability of these new medicines. Some examples of new medicines include:

- Two treatments for early Alzheimer's Disease - **Lecanemab** (Leqembi), a monoclonal antibody targeting the beta-amyloid deposits for treatment of adult patients with early stages of Alzheimer's disease who have either no copies or only one copy of the apolipoprotein E4 gene (ApoE4), and **Donanemab** (Kisunla), another monoclonal antibody acting on a similar target. These were the first two treatments authorised for the treatment of Alzheimer's disease where the treatments have the potential to alter the course of the disease progression. The CHM took inputs from physician experts and patient representatives in giving their final advice for these treatments. ApoE4 homozygous patients who received lecanemab/donanemab were at higher risk of developing adverse effects. In considering the magnitude of benefit on slowing the progression of the disease, the CHM advised that the risk:benefit of lecanemab/donanemab was favourable in the patients who were ApoE4 non-carriers or heterozygous but not in the homozygous group, and therefore testing for the ApoE4 gene should be carried out before treatment. Approval of these products was dependent on a robust pharmacovigilance approach, including a controlled access programme.
- **Imdelltra** (tarlatamab), a medicinal product indicated for the treatment of adult patients with advanced small cell lung cancer with disease progression on or after platinum-based chemotherapy.
- **Tauvid** (Flortaucipir), a new diagnostic radiopharmaceutical product used in a PET scan for adult patients showing signs of cognitive impairment to diagnose Alzheimer's disease.
- **Fruzaqla** (Fruquintinib), a medicine for the treatment of adult patients with metastatic colorectal cancer (CRC) when other treatments have not worked.
- **Vyloy** (Zolbetuximab), a monoclonal antibody that targets the Claudin 18.2 (CLDN18.2) protein found in the stomach lining and is approved for the treatment of adult patients with gastric or gastro-oesophageal junction cancer who are positive for the CLDN18.2 and negative for the human epidermal growth factor receptor 2 (HER2) proteins.
- **Iqirvo** (Elafibranor), a medicine for the treatment of adult patients with a rare type of liver disease known as primary biliary cholangitis (PBC).

- **Truqap** (Capivasertib) is an AKT kinase inhibitor approved for the treatment of patients with advanced hormone receptor positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer which has one or more abnormal PIK3CA, AKT1 or PTEN gene and does not respond to other anti-hormonal based therapies. Capivasertib is authorised for use with fulvestrant in these patients.

Medicines that address unmet clinical need

Some of the new medicines were in therapeutic areas where there was a great unmet medical need and, in such cases, the CHM advised the MHRA on granting either a conditional marketing authorisation (CMA) or a marketing authorisation under exceptional circumstances, where the comprehensive evidence on efficacy and safety was not yet available. This facilitated early access of new medicines to patients. Some examples where medicines were approved under a CMA include:

- **Filspari** (Sparsentan) works by blocking endothelin and angiotensin and lowers the protein in the urine and thereby helps to slow down the progression of the kidney damage in Berger's disease, where Immunoglobulin A (IgA) builds up in the kidneys. Filspari was also granted an orphan medicine designation as the condition is rare.
- **Eqjubi** (Sugemalimab), a monoclonal antibody targeting the programmed death-ligand 1 (PD-L1) for the treatment of adult patients with non-small cell lung cancer.
- **Wainzua** (Eplontersen) for the treatment of adults with polyneuropathy associated with hereditary transthyretin amyloidosis (ATTRv), which is a rare progressive condition that runs in families and is caused by a protein called transthyretin. Eplontersen works mainly by lowering the amount of TTR protein made by the liver. As a result, there is less TTR protein in the blood to form amyloid deposits and cause neuropathy.
- **Joenja** (Leniolisib phosphate) for the treatment of a rare immune disease known as activated phosphoinositide 3-kinase delta syndrome (APDS) in adults and adolescents aged 12 years and over. Joenja was granted an orphan designation as this condition is rare.

Post-pandemic COVID vaccines

Although the public health emergency due to COVID has passed, there is still a need for COVID vaccines and therapeutics to prevent and treat infections with the different emerging strains of the COVID virus particularly in high risk populations. In this regard, the CHM has advised on the following:

- **Nuvaxovid JN.1 vaccine** is a line extension of the existing Nuvaxovid COVID19 vaccine and provides immunity against COVID by targeting the JN.1 subvariants and is licensed for use in adults and adolescents aged 12 years and older. Similarly, a Nuvaxovid vaccine targeting Omicron XBB1.5 subvariant was also approved.
- **Spikevax JN.1 vaccine** is a line extension of the Spikevax COVID-19 vaccine and provides immunity against COVID by targeting the JN.1 subvariants and is licensed for use in adults and children aged 6 months and above.

- **Comirnaty JN.1 vaccine** is a line extension of the existing Comirnaty COVID 19 vaccine and provides immunity against COVID by targeting the JN.1 subvariants and is licensed for use in adults and children aged 6 months and above.
- **Comirnaty KP.2 vaccine** is a line extension of the existing Comirnaty COVID 19 vaccine product and provides immunity against COVID by targeting the KP.2 subvariants and is licensed for use in adults.

Extension of use of approved medicines

The CHM has also advised on the safety and effectiveness of already approved medicines for use in new indications or continued approvability of medicines approved under conditional marketing authorisation based on evaluation of the emerging evidence on benefit and safety. Some examples of such applications include:

- **Wegovy** (Semaglutide), a GLP-1 receptor agonist was approved for a new indication to reduce the risk of overweight and obese adults suffering serious heart problems or strokes. This was previously approved for use in treatment of obesity and for weight management, but with this variation, this became the first weight loss drug prescribed to prevent cardiovascular events in overweight and obese patients with established cardiovascular disease.
- **Vabysmo** (faricimab), a humanised bispecific antibody that inhibits both angiopoietin-2 and vascular endothelial growth factor A (VEGF-A) was approved for a new indication in treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO). This was previously approved for the treatment of visual impairment due to neovascular (wet) age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DMO).
- **Mavenclad** (cladribine) – widening of the indication to include relapsing forms of multiple sclerosis with active disease as defined by clinical or imaging features. The indication was previously restricted for treatment of highly active relapsing multiple sclerosis.
- **Ayvakyt** (Avapritinib) was approved in a new indication for the treatment of adult patients with advanced systemic mastocytosis including aggressive systemic mastocytosis, systemic mastocytosis with an associated haematological neoplasm or mast cell leukaemia. Previously it was approved solely for the treatment of unresectable or metastatic gastrointestinal stromal tumour.
- **Metformin** is a biguanide with antihyperglycaemic effects and also has other effects including lowering hyperandrogenism due to polycystic ovarian syndrome. It was approved in a new indication for ovarian stimulation to support conception in women with polycystic ovarian syndrome. The approved indications of metformin previously were mainly for treatment of type 2 diabetes mellitus.
- **Blinicyto** (Blinatumomab) was approved for a new indication for the treatment of patients with CD19-positive B-precursor acute lymphoblastic leukaemia (ALL) in the consolidation phase. It was previously authorised for other stages of B-cell ALL.
- **Imfinzi** (Durvalumab) was approved for a new indication for use in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by durvalumab as monotherapy after surgery, for the treatment of adults with resectable (tumours ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known EGFR gene mutations or ALK rearrangements. It was previously approved for treatment of locally

advance, unresectable NSCLC and other cancers such as small cell lung cancer, biliary tract cancer, hepatocellular carcinoma and endometrial cancer.

The Early Access to Medicines Scheme (EAMS)

The Early Access to Medicines Scheme (EAMS) helps to give people with life threatening or seriously debilitating conditions early access to new medicines that do not yet have a marketing authorisation, where there is a clear unmet medical need. The CHM gave preliminary advice to the MHRA on two EAMS applications, asking the MHRA to seek more information and justification from the applicants before a final advice can be provided.

Orphan designations

The MHRA offers incentives in the form of market exclusivity and full or partial refunds for marketing authorisation fees to encourage the development of medicines in rare diseases. The CHM advises the MHRA on orphan designation applications and whether the medicine, its effects and the medical condition meets the criteria. The CHM considered and discussed the eligibility of products for orphan designation and over the last year, advised on the grant of orphan designation for products which target rare diseases. Some examples of the products on which the CHM advised the orphan designation include:

- **Agamree** (vamorolone) was approved for treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older. This is a rare condition with a high unmet need and this product received a conditional marketing authorisation as an orphan medicine.
- **Andembry** (Garadacimab) was approved for the routine prevention of recurrent attacks of hereditary angioedema in adult and adolescent patients aged 12 years and older. This product was evaluated for fulfilment of orphan designation criteria and although this was a rare condition, there were other treatments available for this condition and based on the CHM's advice, the applicant proceeded to a marketing authorisation approval without orphan designation.
- **Iqirvo** (Elafibranor) tablets were authorised for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA. As this is a rare condition, the product was authorised as an orphan medicine.
- **Duvyztat** (Givinostat) is another medicine indicated for the treatment of patients aged 6 years of age and older with all genetic variants of Duchenne muscular dystrophy. It received a conditional marketing authorisation as an orphan medicine.

Reclassification of medicines

Reclassification of medicines involves switching the legal status of medicines between Prescription-only medicines (POM), Pharmacy medicines (P) and General Sales List medicines (GSL). New medicines are generally approved as 'prescription-only medicines', but over time, growing confidence in the medicine's role and improved understanding of its side effects can lead to switches to Pharmacy or General Sales List which empower patients' ability to self-care and alleviate the demand for NHS services. The CHM

considered the evidence and justifications supporting the applications for reclassification and advised on reclassification of medicines; examples include:

- POM to P reclassification of **Ovesse** (estriol) vaginal cream for treatment of vaginal atrophy associated symptoms due to oestrogen deficiency of menopause in women aged 50 years and above who have not had a period for at least 1 year.
- POM to P reclassification of melatonin indicated in adults for short-term treatment of jet lag.
- POM to P reclassification of **Dymista** (azelastine hydrochloride, fluticasone propionate) for the relief of symptoms of moderate to severe seasonal allergic rhinitis in adults if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.
- Review of access to loperamide through General Sales and as Pharmacy medicines – consideration of originator marketing authorisation holder (MAH) written representations to the CHM.

Advice on Established/Generic medicines

The CHM also advised on the approvability of several established medicine applications. Established medicines constitute the majority of the medicines used in the UK so the MHRA needs to ensure patients and prescribers in the UK have access to safe and effective medicines of good quality. The advice from CHM in relation to such products included a wide range of topics, such as the balance of the weight of benefits as compared against the risks to the acceptable intake levels of nitrosamine impurities that could be permitted in different medicines. In addition, the CHM advised on the implementation of the Synapse Article 31 referral recommendations with respect to the bioequivalence of critical products for the UK for which companies can be given time to submit new bioequivalence studies.

Policy/Strategy Advice

The CHM also provided advice to the MHRA in shaping the regulatory strategies for the Innovative Licensing and Access Pathway (ILAP). The CHM discussed the proposed revisions for a refreshed ILAP criteria and Target Development Profile (TDP) and provided advice to the MHRA on their draft proposals.

The CHM discussed the clinical trials “notification” framework, which extended the criteria for the notification scheme for initial clinical trial applications and introduced criteria for notification of certain clinical trial substantial amendments. The CHM discussed the proposals and provided advice on the implementation steps in terms of piloting, reviewing and modifying the notification framework as appropriate. Whilst the CHM supported the proposed notification scheme’s extended criteria, the need to focus on the safety of the trial participants was emphasised, as it should be the main consideration in the proposals and the future review. Based on the CHM’s advice, a new clinical trials framework was developed for the UK by the MHRA.

The CHM also held a session on lessons learned from the experience of dealing with the COVID-19 pandemic. A number of positives were identified that should be carried forward such as:

- Establishment of Expert Working Groups which allowed the CHM to receive inputs from a wide range of disciplines.
- Clear distinction between the information gathering part of the meeting, where the invited attendees could contribute, and the decision making part, where the invited attendees would not be present, thus maintaining the independence of the CHM.
- Rolling submission of data and CHM access to raw data was useful in a public health emergency, although this could be overwhelming and would need more signposting in the future.
- Prompt publications of meeting minutes for transparency with additional resource available for this activity in case of a future health emergency.

Some issues were identified that need to be addressed such as:

- Difficulty of operating two different regulatory regimes, one for Great Britain and one for Northern Ireland.
- Poor interaction with the European Medicines Agency (EMA) and it was felt that more interaction with the EMA would have been helpful.
- Difficulties in getting specific detailed case-information on adverse events of interest to inform decision making. It was agreed that systems for gathering medical information from individual cases need to be improved through improved collation and linkage of healthcare databases to support timely identification of adverse events.

In order to support the development of personalised medicines the CHM also recommended the conversion of the Cancer Vaccine Expert Working Group (EWG) which was established in March 2023 to a Highly Personalised Medicines Expert Working Group from May 2024. This new EWG has a broader remit with updated Terms of Reference that covers all personalised medicines rather than only cancer vaccines. The CHM advised the expansion of this group to include additional relevant experts capable of advising on the broader remit.

Additionally, the CHM discussed and advised on the following subjects:

- Absence of dose counters on short-acting Beta-agonists.
- Biosimilars naming guidance.
- Draft guidance for developers of individualised mRNA cancer immunotherapies.
- Publication of “pharmacokinetic data during pregnancy” on the MHRA website and provided inputs based on test summaries for specific medicines such as lamotrigine, phenytoin, levetiracetam and carbamazepine. The CHM was supportive of this approach to disseminate useful information to prescribers and patients. The CHM provided feedback on simplifying the language in the summary to enable delivery of the key messages to lay-people.

Advice to Secretary of State for Health and Social care

The Secretary of State for Health and Social Care and the Minister of Health for Northern Ireland jointly consulted [directly] with the CHM for advice on the known benefits and risks of drugs used for the purposes of gender incongruence and/or gender dysphoria, under the care of private or non-UK prescribers. The CHM's report on the proposed changes to the availability of puberty blockers was finalised on 13 Nov 2024 and published on 24 Jan 2025.

This is available at:

<https://www.gov.uk/government/publications/chms-report-on-proposed-changes-to-the-availability-of-puberty-blockers>

Backlog Clearance

The CHM played a key role in addressing the backlog of clinical trial authorisation applications and marketing authorisation applications built up at the MHRA following the UK's withdrawal from the European Union and the re-organisation at the MHRA, by providing expert advice and recommendations in the following areas:

- Clinical Trials

- Supported the development of the Notification Criteria based on a risk proportionate approach for both initial applications and amendments, where the applications that meet these criteria could be considered approved upon notification to the MHRA.
- Helped to refine the criteria of the notifiable trials before inclusion in the statutory instrument on clinical trials regulations that was laid before Parliament.

- Marketing Authorisation Applications

- The CHM, with the help of one of its main expert advisory groups (EAG), the Chemistry, Pharmacy and Standards (CPS) EAG, reviewed an increased number of papers ranging between 25-40/month (as compared to the previous average around 10 applications) on abridged applications of generic medicinal products with known active substances over the latter part of last year, which helped in clearing the backlog in established medicines applications. This was a significant challenge to all involved to ensure that consistent levels of deep and rigorous scientific analysis of these applications were maintained while clearing the backlog.
- The main issues in these applications were related to quality or joint quality/clinical, which was the expertise of the CPS EAG. The members of the CPS EAG worked in small teams over extended meeting periods to review the increased number of applications, and this provided the necessary assurance to the CHM to consider and endorse as appropriate, the issues identified in these applications expeditiously

Safety of Medicines

The CHM advised on a range of product specific issues relating to the safety of medicines over the course of the year, including:

- Newly analysed data on the reproductive risks associated with **sodium valproate** and the potential for epigenetic effects with advice of the Valproate Epigenetics Expert Working group taken into consideration.
- Recommendations of the Valproate Epigenetics Expert Working Group on the updates to the **valproate** licence and need for further research.
- Expansion of the Terms of Reference and membership of an antidepressant risk minimisation expert working group looking at how the risk of suicidal behaviours and sexual dysfunction where symptoms continue are communicated in patient leaflets and ways risk minimisation can be improved.
- Safety signals associated with and plans for the ongoing monitoring of the safety of the **RSV vaccine**.
- Risk minimisation improvements for **paracetamol** including the consideration of further pack size restrictions.
- Addition of psychological adverse effects to the **Kaftrio** product information.
- Plans for independent review of the Plasma-derived medicinal products in the context of variant Creutzfeldt-Jakob disease (CJD).

The CHM provided advice on risk management plans for all applications for marketing authorisation assessment for all new active substances and all known active substances.

Involving patients' views at the CHM

Patient views are essential in regulatory decision-making on the safety of medicines. In 2024, the patient voice, and their lived experience, was represented through a variety of patient engagement strategies including inviting patients and their representatives to the CHM meeting, through patient charity engagement and through the consideration of written input from patients in all formats including Yellow Card reports and direct correspondence.

Following the publication of the CHM Isotretinoin Implementation Expert Advisory Working Group (IIEAWG) on 31 October 2023, the CHM reviewed initial feedback from stakeholders involved in the implementation of the new regulatory requirements for **isotretinoin**. As a result of this stakeholder input the CHM advised on the insertion of an addendum to the IIEAWG report in order to facilitate safe implementation of the new recommendations.

The CHM, as per the terms of reference, also has a duty to ensure that information relating to adverse reactions was collected and scrutinised throughout 2024. The CHM provided advice on the trends and themes in the Pharmacovigilance statistics presented at every meeting and on specific new emerging safety signals from Yellow Card data. The CHM considered and provided advice on the UK implications of any safety related recommendations for product information highlighted by the EU Pharmacovigilance Risk Assessment Committee minutes discussed at each meeting.

The CHM take assurance that the MHRA has systems in place for reporting of suspected adverse drug reactions and for review of these and other reports. However, the CHM continues to have an important role in giving independent advice on these safety data where needed. In 2024, 101,000 adverse drug reactions reports were received by the MHRA; 24% from patients, 32% from Industry and 43% from healthcare professionals.

Highlights of our 2024 achievements

Authorisation of safe and effective new medicines is central to advancing public health as they offer new opportunities for treating certain diseases. In 2024:

The CHM reviewed and advised on **442** papers over 12 scheduled monthly meetings, the details of these are:

Type of Product

360 papers were on Chemical products including **1** radiopharmaceutical product and **30** products with new active substances

32 papers were not related to any specific medicinal products

50 papers were on Biological products

Groups seeking CHM advice

391 of the papers were by the licensing (Healthcare Quality and Access) group. This included:

- **384*** papers on applications for medicinal products (including new actives and known active substances) including **128** Risk Management Plan assessments by the S&S group
- **7** papers on general topics

44 of the papers were led by the post-licensing (Safety and Surveillance, S&S) group, which included **12** papers on Pharmacovigilance Statistics (Yellow Card data) and **11** papers on PRAC highlights

7 papers were by other groups including **3** from Science, Research & Innovation group and **4** from the Department of Health & Social Care

* These **384** papers concerned application for **641** medicinal products, as some papers would cover multiple medicinal products of different strengths.

Stage of advice

256 papers were preliminary advice on applications

128 papers were final advice on applications

58 papers were on strategy and/or process

The above papers included **2** papers under the Early Access to Medicines Scheme

Additionally, **1** ad-hoc/extraordinary meeting was held in March by the CHM where they provided advice on two applications for medicinal products, one biological product and the other a chemical medicinal product.

Once a medicine has been authorised, the MHRA continuously monitors the quality, safety and efficacy of the medicine to keep patients safe.

* The licensing authority seeks advice from the CHM by the form of a "paper". A paper may cover a number of products, either pre-licensing or post-licensing, to ask for CHM's preliminary or final advice. Preliminary Advice is CHM's provisional opinion on the product concerned, as described in Schedule 11 of the HMR. CHM's recommendation is final following representations made by the applicant (Sch 11 of the HMR).

Breakdown of advice provided by the Commission on Human Medicines, Expert Advisory Groups (EAG), Expert Working Groups (EWG) in 2024

CHM, Expert Advisory Groups and Expert Working Groups	Abbrev.	Papers Considered and Advice Given	
		by meeting	by writing
Commission on Human Medicines	CHM	444	1
Chemistry, Pharmacy and Standards	CPS EAG	105	-
Clinical Trials, Biologicals & Vaccines	CTBV EAG	2	6
Pharmacovigilance	P EAG	35	1
Cardiovascular, Diabetes, Renal, Respiratory and Allergy	CDRRA EAG	6	3
Gastroenterology, Rheumatology, Immunology & Dermatology	GRID EAG	4	1
Paediatric Medicines	PM EAG	20	1
Oncology and Haematology	OH EAG	13	1
Neurology, Pain & Psychiatry	NPP EAG	4	4
Medicines for Women's Health	MWH EAG	12	3
Highly Personalised Medicines Expert Working Group		14	-
Valproate Epigenetics Expert Working Group		1	-
Valproate Implementation Expert Working Group		7	-
Total Papers Considered and Advice Given		688	

Summary reports based on the minutes of each meeting from the CHM's Expert Advisory Groups are published on the [GOV.UK](https://www.gov.uk) website.

Membership

Chair and Members of the Commission on Human Medicines are appointed under Regulation 9 of the Human Medicines Regulations 2012, and are expected to abide by the [Code of Conduct for Board Members of Public Bodies](#) and [Governance Code for Public Appointments](#), as part of their terms and conditions of appointment. Chairs and Members of the expert advisory groups and working groups are also expected to abide by the [Code of Practice for Scientific Advisory Committees](#).

The CHM has 20 members (including the Chair) appointed by Ministers and meets 12 times a year for up to two days. In 2024, eight of the 12 meetings were two-day meetings. The work of the CHM is supported by ten established Expert Advisory Groups (EAGs) as well as three Expert Working Groups (EWG) comprising of 179 experts.

EWGs are created by the CHM, in discussion with the Licensing Authority, to advise the CHM on particular specialist issues. The CHM wishes to record its gratitude and appreciation of the valuable work of its Expert Advisory Groups and Working Groups. Details of members of the CHM, its expert advisory groups and working groups are listed in this report.

Costs

Commissioners are entitled to claim an attendance fee of £325 per day or a Chair's fee of £500. Expert Advisory Group members are entitled to claim an attendance fee of £200 or a Chair's fee £325. Travel and subsistence are also payable within standard Department of Health & Social Care guidelines.

If you are interested in learning more about CHM's you can find further information on the Gov.uk website: <https://www.gov.uk/government/organisations/commission-on-human-medicines>

Code of Practice for the Commission on Human Medicines and other expert advisory committees

All chairs, members, co-opted members and invited and patient experts of all our scientific advisory committees are required to declare any personal and non-personal interest, or any significant interests held by close family or friends, which may be reasonably perceived to influence their judgement in performing their functions and obligations.

Furthermore, all chairs and members must declare their interest in any items being discussed at meetings and will declare any new conflict of interest at the earliest opportunity in advance of the next meeting they attend and openly at that next meeting. These are recorded in the meetings' minutes. Where a member declares a potential conflict at meetings, it is recorded in the minutes and the member's subsequent involvement is dealt with depending on the topic, forum and type of interest or conflict, in accordance with the Code of Practice.

The principles in the Code also apply to observers and invited experts who are asked to contribute written advice and do not attend committee meetings.

The Code of Practice is published on:

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1103036/2022.09.07_The_Code.pdf

The list of declared interests for chairs and members of CHM (and EAGs, EWGs and ad-hoc groups) is available below.

Membership of the Commission on Human Medicines (CHM)

Post	Name and title	Affiliations (if applicable)
Chair	Professor Sir Munir Pirmohamed MB ChB (Hons) PhD FRCP FRCP (Edin) FBPhS, FFPM (Hon) FMedSci	David Weatherall Chair of Medicine, University of Liverpool, NHS Chair of Pharmacogenetics, Director of the Wolfson Centre for Personalised Medicine, Director of the Centre for Drug Safety Science
Vice Chair	Professor Steven Cunningham MBChB PhD FRCPCH	Professor of Paediatric Respiratory Medicine, University of Edinburgh and Honorary Consultant, Royal Hospital for Children and Young People, NHS Lothian, Edinburgh
Lay Member	Mrs Julia Cons	
Lay Member	Mr David Crundwell	
Member	Professor Amanda Adler MD PhD FRCP	Professor of Diabetic Medicine and Health Policy, University of Oxford
Member	Professor Jamie Coleman MD MA (Med Ed) FRCP FBPhS	Consultant Physician, University Hospitals Birmingham NHS Foundation Trust and Honorary Professor in Clinical Pharmacology and Medical Education, University of Birmingham
Member	Professor Paul I Dargan MB BS FRCP Edin FACMT FRCP ERT FAACT FEAPCCT FBPhS MAE FCRaz FRSB	Consultant Physician and Professor of Clinical Toxicology, Guy's and St Thomas' NHS Foundation Trust, London Professor of Clinical Toxicology, King's College London
Member	Professor David Dockrell MB BCh MD FRCPI FRCP (Glas) FACP	Professor of Infection Medicine, University of Edinburgh
Member	Dr Jamie Fraser BSc (Hons) MBChB MRCGP	GP Partner, Southside Surgery, Inverness
Member	Professor David Hunt MB BChir FRCP PhD	Consultant Neurologist, NHS Lothian Professor of Neuroinflammatory Medicine, University of Edinburgh
Member	Professor David Moore MBChB MD MSc DTM&H	Professor of Infectious Diseases and Tropical Medicine, London School of Hygiene and Tropical Medicine and Consultant in Infectious Diseases and Tropical Medicine, Hospital for Tropical Diseases, University College London Hospital

Member	Dr Gerri Mortimore PhD; MSc Advanced Practice; PgCert (IPPE); BA(Hons) Health Studies; iLM. RGN; NMP; FHEA	Associate Professor in Advanced Clinical Practice; NICE Nurse Expert Advisor
Member	Professor Sandosh Padmanabhan MBBS MD PhD FRCP(Glasg) FRCP(Edin) FBPhS FBIHS	Professor of Cardiovascular Genomics and Therapeutics, University of Glasgow
Member	Professor Poulam Patel ¹ PhD, MBBS, FRCP	Professor of Clinical Oncology, University of Nottingham
Member	Professor Yvonne Perrie BSc Hons MRPharmS FAPS FSB PhD	Chair in Drug Delivery, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow. Scotland
Member	Professor Rui Providencia MD PhD	Institute of Health Informatics Research, University College London. Consultant Cardiologist & Cardiac Electrophysiologist, Barts Health NHS Trust
Member	Dr Vanessa Raymont MBChB MSc MRCPsych	Senior Clinical Researcher, University of Oxford and Honorary Consultant Psychiatrist, Oxford Health NHS Foundation Trust
Member	Professor Marc Turner ² MB ChB PhD MBA FRCP FRCPATH FRSE	Director, Scottish National Blood Transfusion Service
Member	Professor Heather M Wallace PhD FRCPATH FRSC FRSB FBTS FBPhS ERT	Professor Emerita of Biochemical Pharmacology and Toxicology, University of Aberdeen
Member	Professor Christopher Weir ³ BSc (Hons) PhD MSc FRSS C.Stat	Personal Chair in Medical Statistics and Clinical Trials, Usher Institute, University of Edinburgh
Member	Professor Anthony Williams BSc MSc MRCP, FRCPATH, PhD	Professor of Translational Medicine and Honorary Consultant in Clinical Immunology and Allergy, University of Southampton and University Hospital Southampton NHS Trust
Member	Dr Martin Wilson MB ChB, MPhil (Glasgow), FRCP(Edin)	Consultant Physician in Care of the Elderly, Raigmore Hospital, Inverness

¹ Reappointed 05/07/2024

² Reappointed 05/07/2024

³ Reappointed 05/07/2024

CHM Co-opted Members, Invited Experts and Observers

Post	Name and title	Affiliations (if applicable)
Co-opted Member (May-Dec)	Dr Jamie Fraser BSc (Hons) MBChB MRCP	GP Partner, Southside Surgery, Inverness
Co-opted Member (Jun)	Dr Majella Lane BSc PhD	Senior Lecturer in Pharmaceutics, UCL School of Pharmacy
Co-opted Member (Nov)	Dr Jonathan Lord MD FRCOG FHEA	Consultant Obstetrician and Gynaecologist, Royal Cornwall Hospitals NHS Trust
Invited Expert (Jan)	Prof Jon S. Friedland MA PhD FRCP FRCPE FRCPI FESCMID FMedSci	Deputy Vice-Chancellor (Research & Enterprise), St. George's, University of London
Invited Expert (Jan)	Professor Richard J C Gilson MD FRCP	Professor of Sexual Health & HIV Medicine, Director of the UCL Centre for Clinical Research in Infection & Sexual Health
Invited Expert (Jan, Mar, Jul)	Professor Gillian M Hawksworth MBE PhD FFRPS FRPharmS (Hon) DSc	Academic Community Pharmacist, Visiting Fellow at University of Huddersfield & Past President of the RPSGB
Invited Expert (Jan)	Dr Siraj Misbah MBBS (Hons) MSc FRCP FRCPATH	National Clinical Director, Blood and Infection Programme of Care, NHS England, Consultant Immunologist, Lead for Clinical Immunology, Oxford University Hospitals, John Radcliffe Hospital, Oxford
Invited Expert (Jan)	Ms Rebecca Penzer-Hick	Senior Clinical Lecturer, Centre of Postgraduate Medicine and Public Health Department of Clinical, Pharmaceutical and Biological Sciences, University of Hertfordshire
Invited Expert (Jan)	Professor Stuart H Ralston MB ChB MD FRCP FFPM (Hon) FMedSci FRSE	Versus Arthritis Professor of Rheumatology, Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital, Edinburgh
Invited Expert (Jan, Dec)	Dr Jane Ravenscroft	Consultant Dermatologist at Nottingham University Hospital and Honorary Assistant Professor at the Centre for Evidence Based Dermatology, Nottingham and Chair of the Isotretinoin Implementation EWG
Invited Expert (Jan)	Professor Sobha Sivaprasad MBBS MS DM FRCS FRCOphth	Consultant Ophthalmologist, Moorfield's Eye Hospital

Invited Expert (Jan, Feb, Sep, Dec)	Professor Kevin M G Taylor BPharm PhD FRPharmS	Emeritus Professor of Clinical Pharmaceutics, UCL School of Pharmacy, London
Invited Expert (Feb)	Dr Robert Andrews	Senior Lecturer FHEA, Data Hub at Heath, Cardiff
Invited Expert (Feb)	Dr Brendan Fish BSc PhD	Director of Biologics & RNA Centre of Excellence
Invited Expert (Feb, Apr, May, Jul)	Professor Robert Howard	Professor of Old Age Psychiatry, Division of Psychiatry, University College London
Patient Expert (Feb)	Patient Expert 1	
Invited Expert (Apr)	Dr Pawan Gupta FRCA, MD	Consultant Anaesthetist & Hon. Clinical Associate Professor Leeds Teaching Hospitals / University of Leeds / Malignant Hyperthermia Unit
Invited Expert (Apr)	Professor Darragh Murnane PhD BSc (Pharm) PhD MRPharmS	Professor of Pharmaceutics and Associate Dean (Enterprise), University of Hertfordshire
Invited Expert (Apr, May)	Professor James Rowe	Professor of Cognitive Neurology, University of Cambridge
Invited Expert (Apr)	Mr Mark Stringer	Regional Quality Assurance Specialist East of England
Invited Expert (May)	Dr Rasha Al-Qurainy MD FRCP MSc	Clinical Lead and Consultant in Palliative Medicine, Camden, Islington and UCLH Palliative Care Service, Central and Northwest London NHS Foundation Trust
Patient Experts (Jun)	Patient Experts 2	
Invited Expert (Jun)	Professor Giovanni Baranello MD PhD	Professor of Paediatric Neuromuscular Disorders, Honorary Consultant in Paediatric Neuromuscular Diseases, UCL Great Ormond Street Institute of Child Health & Great Ormond Street Hospital NHS Foundation Trust
Invited Expert (Jun, Sep)	Professor Sobha Sivaprasad MBBS MS DM FRCS FRCOphth	Consultant Ophthalmologist, Moorfield's Eye Hospital

Invited Expert (Jul)	Professor William (Bill) Newman MA PhD FRCP FMedSci	Professor of Translational Genomic Medicine, University of Manchester
Invited Expert (Aug)	Professor Philip (Phil) Hannaford FRSE	Emeritus Professor of Primary Care University of Aberdeen
Invited Expert (Aug)	Professor Chris Fox	Clinical Professor in Haematology Faculty of Medicine & Health Sciences, University of Nottingham
Invited Expert (Sep)	Dr Indi Bannerjee	Consultant Paediatric Endocrinologist, Central Manchester & Manchester Children's Foundation Trust
Invited Expert (Sep)	Professor Tim Cheetham	Professor of Clinical Paediatric Endocrinology, Newcastle upon Tyne Hospitals and honorary consultant paediatrician at Royal Victoria Infirmary, Newcastle upon Tyne
Invited Expert (Oct)	Professor Gary Cook MBBS MSc MD FRCR FRCP	Professor of Molecular Imaging / Honorary Consultant Physician, King's College London and Guy's & St Thomas' Hospitals
Invited Expert (Nov)	Professor Chris Goldring BSc PhD PGCert FBPhS	Professor of Pharmacology, Department of Pharmacology and Therapeutics, The University of Liverpool.
Invited Expert (Nov)	Professor Ben Burton	Honorary Professor, University of East Anglia, Consultant Ophthalmologist, James Paget University Hospital President of the Royal College of Ophthalmologists
Invited Expert (Nov)	Dr Livia Martucci MBBS PhD MRCPsych	Consultant Perinatal Psychiatrist, South London and Maudsley NHS Foundation Trust (SLaM), Chair of the Perinatal Faculty at RCPsych
Patient Expert (Nov)	Patient Expert 3	
Patient Expert (Dec)	Patient Expert 4	
Patient Expert (Dec)	Patient Expert 5	
Invited Expert (Dec)	Dr Piya Sen Gupta	Consultant in in diabetes and endocrinology, Guy's & St Thomas' NHS Foundation Trust
Invited Expert (Dec)	Dr Tamara Griffiths	President, British Association of Dermatologists
Invited Expert (Dec)	Professor Michael Arden-Jones	Vice-President of BAD

Observers	Representatives of the Department of Health and Social Care (DHSC) have observed the following meetings: <ul style="list-style-type: none"> • Jan, Sep, Oct
Observers	Officials from National Institute for Health and Care Excellence (NICE) have observed the following meetings: Apr, May, Jun, Jul, Aug, Sep, Oct, Nov, Dec
Observers	Officials from United Kingdom Health Security Agency (UKHSA) have observed the following meetings: <ul style="list-style-type: none"> • Sep, Oct
Observers	Officials from Devolved Nations Administrations (Wales) have observed the following meetings: <ul style="list-style-type: none"> • Sep, Oct
Observers	Officials from Devolved Nations Administrations (Scotland) have observed the following meetings: <ul style="list-style-type: none"> • Feb, Sep, Oct
Observers	Officials from Health Canada have observed the following meetings: <ul style="list-style-type: none"> • Nov
Observers	Officials from Therapeutic Goods Administration (TGA), Australia, have observed the following meetings: <ul style="list-style-type: none"> • Nov

Membership of the Cardiovascular, Diabetes, Renal, Respiratory & Allergy Expert Advisory Group (CDRRA EAG)

Post	Name and title	Affiliations (if applicable)
Chair	Professor Amanda Adler MD PhD FRCP	Professor of Diabetic Medicine and Health Policy, University of Oxford
Member	Dr Amine Boualem MD MRCGP PGDip(Diabetes) AHEA	GP Partner, East Barnwell Health Centre, Cambridge
Member	Professor Mark Evans Bsc MB BS MD FRCP	Professor of Diabetic Medicine, University of Cambridge and Consultant Physician, Cambridge University Hospitals
Member	Professor William G. Herrington MA(Cantab) MBBS(London) MD(Cantab) FRCP(London)	Professor of Trials and Epidemiology of Kidney Disease. Renal Studies Group, Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford; Honorary Consultant Nephrologist, Oxford Kidney Unit
Member	Dr Patrick Holmes MB BS MSc MRCGP	GP Partner St. George's Medical Practice, Darlington
Member	Dr Wajid Hussain BSc (Hons) MB ChB (Hons) MSc FRCP	Consultant Cardiologist, Royal Brompton and Harefield Hospitals, Part of Guys and St Thomas' NHS Foundation Trust
Member	Dr Hassan Kahal ⁴ PhD, FRCP, PG CertMedEd, SCOPE,	Consultant in Diabetes, Endocrinology, and Obesity Medicine, Southmead Hospital, North Bristol NHS Trust, Bristol
Member	Professor Sandosh Padmanabhan MBBS MD PhD FRCP(Glasg) FRCP(Edin) FBPhS FBIHS	Professor of Cardiovascular Genomics and Therapeutics, University of Glasgow
Member	Professor Patrick Mark MB CHB (Hons) PhD FRCP (Glasg)	Professor of Nephrology & Honorary Consultant Nephrologist, University of Glasgow and Glasgow Renal and Transplant Unit, Queen Elizabeth University Hospital, Glasgow
Member	Professor Theresa McDonagh BSc (Hons), MB ChB (Hons), MD (Distinction), FRCP, FESC, FHFA	Consultant Cardiologist, King's College Hospital, London & Professor of Heart Failure King's College, London
Member	Dr Shuaib Nasser MA MBBS MD FRCP	Consultant Allergist and Respiratory Physician, Head of Allergy Cambridge University Hospital NHS Foundation Trust, Cambridge

⁴ Appointed 02/12/2024

Member	Professor John Petrie ⁵ BSc(Hons) MBChB PhD FRCP(Glasg) FRCP(Edin)	Professor of Diabetes & Director of Glasgow Clinical Trials Unit, University of Glasgow
Member	Professor Anita K Simonds MD FRCP FERS	Professor Emeritus of Respiratory and Sleep Medicine, National Heart and Lung Institute, Imperial College, London & Honorary Consultant Respiratory and Sleep Physician, Royal Brompton & Harefield Hospital, Sydney Street, London, Harveian Librarian, Royal College of Physicians, London
Member	Dr Rona Smith ⁶ MA(Cantab) MB BChir(Cambridge) MD(Cantab) MRCP(London)	Associate Professor of Nephrology, University of Cambridge; Honorary Consultant in Nephrology and Vasculitis, Cambridge University NHS Foundation Trust.
Member	Professor Michael Steiner MB BS BSc MD FRCP	Professor in Respiratory Medicine and Honorary Consultant, Dept of Respiratory Science, University of Leicester
Member	Professor Sarah Wild ⁷ MB BChir MSc PhD FRCPE FFPH	Professor of Epidemiology, Honorary Consultant in Public Health, Usher Institute, University of Edinburgh

⁵ Appointed 02/12/2024

⁶ Appointed 02/12/2024

⁷ End of appointment 14/07/2024

Membership of the Chemistry, Pharmacy and Standards Expert Advisory Group (CPSEAG)

Post	Name and title	Affiliations (if applicable)
Chair	Professor Yvonne Perrie BSc Hons MRPharmS FAPS FSB PhD	Chair in Drug Delivery, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow. Scotland
Vice Chair	Dr Majella Lane BSc PhD	Senior Lecturer in Pharmaceutics, UCL School of Pharmacy
Lay Member	Mrs Ruth Paulin BPharm MRPharmS	
Member	Professor Hannah Batchelor BSc PhD	Professor of Pharmaceutics and Biopharmaceutics, Strathclyde Institute of Pharmaceutical and Biomedical Sciences, University of Strathclyde
Member	Dr Federico Brucoli Pharm. D. PhD CChem MRSC mGPhC FHEA	Senior Lecturer in Medicinal Chemistry, Leicester School of Pharmacy, De Montfort University, Leicester
Member	Professor Barbara R Conway BSc (Pharm) PhD FRPharmS CMgr FCMI	Head of Pharmacy and Professor of Pharmaceutics, University of Huddersfield, Huddersfield
Member	Professor Ben Forbes BPharm PhD	Professor of Pharmaceutics, Institute of Pharmaceutical Science, Kings College London
Member	Professor Nikoletta Fotaki MSc, PhD, FAAPS	Professor of Biopharmaceutics, Department of Life Sciences, Centre for Therapeutic Innovation (CTI), University of Bath
Member	Mr Robert Lowe BPharm FRPharmS	Practising Hospital Pharmacist, Specialist Pharmacy Services - East of England
Member	Professor Luigi (Gino) Martini BSc (Hons), PhD, MBA, FRPharmS, FRSC	Chief Executive Precision Health Technology Accelerator (PHTA), University of Birmingham Honorary Professor in Pharmacy, University of Birmingham
Member	Professor Afzal R Mohammed BPharm PhD	Professor of Pharmaceutics, Aston Pharmacy School, Aston University
Member	Professor Darragh Murnane PhD BSc (Pharm) PhD MRPharmS	Professor of Pharmaceutics and Associate Dean (Enterprise), University of Hertfordshire

Member	Professor Susannah E Walsh PhD BSc MBA	Head of School, Professor of Pharmaceutical Microbiology, Pharmacy and Life Sciences, Robert Gordon University
Member	Mr Hadar Zaman MPharm, MFRPSII, IPresc, FHEA	Chief Pharmacist, North Cumbria Integrated Care NHS Foundation Trust

Membership of the Clinical Trials, Biologicals & Vaccines Expert Advisory Group (CTBVEAG)

Post	Name and title	Affiliations (if applicable)
Chair	Professor Marc Turner MB ChB PhD MBA FRCP FRCPATH FRSE	Director, Scottish National Blood Transfusion Service
Lay Member	Dr Kirstie Shearman LLB MA PhD	Policy Manager, Health Research Authority
Member	Professor Farzin Farzaneh DPhil FRCPATH FRSB	Professor of Molecular Medicine, King's College London. Honorary Consultant in Specialist Medicine, King's College Hospital NHS Trust
Member	Professor Chris Goldring BSc PhD PGCert FBPhS	Professor of Pharmacology, Department of Pharmacology and Therapeutics, The University of Liverpool.
Member	Professor Andrew Pollard ⁸ PhD FRCPCH FMedSci	Chair of the Joint Committee on Vaccination and Immunisation; Professor of Paediatric Infection and Immunity, University of Oxford
Member	Dr Robin Thorpe PhD FRCPATH	Retired, Head, Division of Biotherapeutics, National Institute for Biological Standards and Control (NIBSC)
Member	Professor Christina Yap MSci PhD Cstat	Professor of Clinical Trials Biostatistics, Team Leader in Early Phase and Adaptive Trials Team, ICR-Clinical Trials and Statistics Unit, The Institute of Cancer Research

⁸ End of appointment 16/07/2024

Membership of the Gastroenterology, Rheumatology, Immunology & Dermatology Expert Advisory Group (GRIDEAG)

Post	Name and title	Affiliations
Chair	Professor Anthony Williams BSc MSc MRCP FRCPPath PhD	Professor of Translational Medicine and Honorary Consultant in Clinical Immunology and Allergy, University of Southampton and University Hospital Southampton NHS Trust
Lay Member	Mr James Pitayanukul ⁹ BSc (Hons) MSc CA	
Member	Professor Michael Ardern-Jones BSc MBBS DPhil FRCP	Associate Professor, University of Southampton and Consultant Dermatologist
Member	Professor Anjan Dhar DM, MD (Medicine), FRCPE, AGAF, Cert. Med. Ed, FHEA	Professor of Medicine (Teesside University), Consultant Gastroenterologist, Clinical Lead for UGI Cancers, County Durham & Darlington NHS Foundation Trust
Member	Dr Shahida Din BMSc, MBChB, PhD, FRCP (Edin)	Consultant Gastroenterologist & NHS Research Scotland Clinician, NHS Lothian; Honorary Senior Clinical Lecturer, University of Edinburgh
Member	Professor Celia Moss OBE BA(Hons) MB BS MA MRCP DM FRCP MRCPC	Honorary Consultant Dermatologist, Birmingham Women's and Children's NHS FT; Honorary Professor of Paediatric Dermatology, University of Birmingham
Member	Professor Stuart Ralston MB ChB MD FRCP FMedSci FRSE FFPM (Hon)	Professor of Rheumatology, University of Edinburgh
Member	Dr Ravishankar Sargur MD, FRCPPath, FRCP, MBA	Consultant Clinical Immunologist and Clinical Lead for Laboratory Immunology, Northern General Hospital, Sheffield
Member	Professor Nidhi Sofat PhD MBBS FRCP PGCert FHEA	Professor of Rheumatology, City St Georges University London and St George's University Hospitals NHS Foundation Trust

⁹ Appointed 22/03/2024

Membership of the Infection Expert Advisory Group (IEAG)

Post	Name and title	Affiliations (if applicable)
Chair	Professor David Dockrell MB BCh MD FRCPI FRCP (Glas) FACP	Professor of Infection Medicine, University of Edinburgh
Lay Member	Mrs Stella O'Brien MA (Hons)	
Member	Professor Brian Angus BSc MBChB MA (Oxon) MD (Glas) DTM&H FRCP FFTM (Glas)	Reader in Infectious Diseases and Professor of Practice, Medical Education, Chair of the UK Malaria Expert Advisory Group (UKMEAG)
Member	Dr Michael Brown BA BM BCh FRCP PhD DTM&H	Consultant Physician, Infectious Diseases & Acute Medicine, & Clinical Director, Division of Infection, University College London Hospitals NHS Foundation Trust & Honorary Associate Professor, Clinical Research Sept, London School of Hygiene & Tropical Medicine
Member	Professor Geraint Rhys Davies BM DTM&H PhD FRCP	Professor of Infection Pharmacology, University of Liverpool, Honorary Consultant in Infectious Diseases, Liverpool University Hospitals Foundation Trust
Member	Dr Andrew Freedman M.A, M.B, B. Chir, M.D, FRCP (Lond.), FRCP (Edin.)	Reader in Infectious Diseases, Cardiff University School of Medicine/ Hon. Consultant Physician, University Hospital of Wales
Member	Professor Richard J C Gilson MD FRCP	Professor of Sexual Health & HIV Medicine, Director of the UCL Centre for Clinical Research in Infection & Sexual Health
Member	Dr Louis Grandjean MBBS BSc MSc PhD MRCPCH	Associate Professor Paediatric Infectious Diseases Great Ormond Street Hospital and University College London
Member	Dr Lim S Jones MBBCh, PhD, FRCPATH.	Consultant Microbiologist, Public Health Wales Microbiology, Cardiff; Clinical Lead Specialist Antimicrobial Chemotherapy Unit, Cardiff; Chair of the All Wales Medical Microbiology Development & Standardisation Group
Member	Dr Matthias Schmid ¹⁰ MD FRCP DTMH	Consultant Physician, Head of Department of Infection & Tropical Medicine, Directorate of Elective Studies Newcastle University, Royal Victoria Infirmary, Newcastle upon Tyne

¹⁰ Reappointed 09/09/2024

Membership of the Medicines for Women's Health Expert Advisory Group (MWHEAG)

Post	Name and title	Affiliations
Chair	Professor Philip Hannaford ¹¹ MBChB MD FRCGP FFPH FFSRH FRSE	Emeritus Professor of Primary Care, University of Aberdeen
Vice Chair	Dr Diana Wellesley FRCP	Honorary Consultant and Honorary Senior Lecturer in Clinical Genetics, Wessex Clinical Genetics Service, Princess Anne Hospital Southampton
Lay Member	Dr Caitlin Dean RGN MSc PhD	Chair Trustee, Pregnancy Sickness Support
Lay Member	Ms Linda Pepper BA MA (Education)	Independent Consultant: patient and public involvement in healthcare
Member	Dr Kenneth Hodson MD MBChB MRCP(UK) MRCOG	Head of UK Teratology Information Service UK Teratology Information Service
Member	Dr Sylvia Kama-Kieghe ¹² FRCGP FRSM FRSPH DFSRH	Consultant in General Practice and Urgent Care, Sheffield GP Out of Hours. GP Tutor and Examiner, University of Sheffield. Digital Health Educator and Clinical Lead, Alevyn Ltd.
Member	Dr Asha Kasliwal FRCOG FFRSH FRCGP (Hon) FFPH (Hon)	Consultant in Community Gynaecology and Reproductive Health, Manchester University NHS Foundation Trust Hathersage Centre
Member	Dr Jonathan Lord MD FRCOG FHEA	Consultant obstetrician and gynaecologist, Royal Cornwall Hospitals NHS Trust
Member	Dr Lucy MacKillop ¹³ BM BCh MA(Oxon.) FRCP FRCOG Ad Eundem	Consultant Obstetric Physician and Honorary Senior Clinical Lecturer, Oxford University Hospitals NHS Foundation Trust, Oxford

¹¹ Reappointed 11/04/2024

¹² Appointed 24/04/2024

¹³ Stepped down 08/05/2024

Member	Professor Laura A Magee ¹⁴ MD (Hons) MSc FRCPC CertClinPharm FACP FRCOG	Professor of Women's Health, King's College London
Member	Dr Louise Massey MBChB FFSRH FFPH	Consultant in Sexual and Reproductive Health Aneurin Bevan University Health Board
Member	Dr Julia Prague MBBS PhD MRCP(UK) BSc	Consultant in Endocrinology, Diabetes, and General Internal Medicine, Royal Devon and Exeter NHS Foundation Trust, and Honorary Senior Clinical Lecturer, College of Medicine and Health, University of Exeter
Member	Professor Stuart Ralston MB ChB MD FRCP FMedSci FRSE FFPM (Hon)	Professor of Rheumatology, University of Edinburgh, Western General Hospital, Edinburgh
Member	Professor Laurie Tomlinson MBBS MSc PhD	NIHR research Professor, Faculty of Epidemiology and Population Health London School of Hygiene & Tropical Medicine

¹⁴ Appointed 24/04/2024

Membership of the Neurology, Pain & Psychiatry Expert Advisory Group (NPPEAG)

Post	Name and title	Affiliations
Chair	Professor David Hunt MB BChir FRCP PhD	Consultant Neurologist, NHS Lothian Professor of Neuroinflammatory Medicine, University of Edinburgh
Member	Dr Lisa Brownell BSc(Hons) MBChB PGCertMedEd FHEA FRCPsych	Associate Medical Director, Birmingham and Solihull Mental Health NHS Foundation Trust Chair of Area Prescribing Committee, Birmingham, Sandwell, Solihull and Environs
Member	Professor Naomi Fineberg BA Hons MB BS MA MRCPsych	Consultant in General Psychiatry, Hertfordshire Partnership University NHS Foundation Trust
Member	Dr Barry Mark Miller MB ChB FRCA FFPMRCA	Consultant in Pain Medicine and Anaesthesia, Bolton NHS Foundation Trust. Board Member of the Faculty of Pain Medicine
Member	Professor David G C Owens MD (Hons) FRCP FRCPsych	Professor Emeritus of Clinical Psychiatry, the University of Edinburgh
Member	Dr Waqar Rashid MBBS BSc MRCP(UK) PhD	Consultant and Honorary Clinical Senior Lecturer in Neurology, Brighton and Sussex University Hospitals NHS Trust, member of the Multiple Sclerosis Society
Member	Dr Fergus Rugg-Gunn ¹⁵ MB BS MRCP PhD	Consultant Neurologist, National Hospital for Neurology and Neurosurgery Queen Square, London
Member	Dr Aditya Sharma MBBS MD MRCPsych PhD	Clinical Senior Lecturer and Honorary Consultant in Child and Adolescent Psychiatry at Newcastle University and Cumbria, Northumberland Tyne and Wear NHS Foundation Trust
Member	Dr Hoo Kee Tsang BSc(Hons) MB BCh FRCA FFPMRCA	Consultant in Pain Medicine and Anaesthesia, Clinical Director of Pain Services, Liverpool University Hospitals NHS Foundation Trust, member of the Royal College of Anaesthetists and the Faculty of Pain Medicine training and assessment committees

¹⁵ Reappointed 21/01/2024

Membership of the Oncology & Haematology Expert Advisory Group (OHEAG)

Post	Name and title	Affiliations
Chair	Professor Poulam M Patel ¹⁶ PhD MBBS FRCP	Professor of Clinical Oncology, University of Nottingham
Vice Chair	Professor James Spicer FRCP PhD	Professor of Experimental Cancer Medicine, King's College London, Consultant in Medical Oncology, Guy's & St Thomas' NHS Foundation Trust
Member	Professor Janet E Brown FRCP MD MSc BMedSci MBBS	Academic Unit of Clinical Oncology, Department of Oncology and Metabolism, Weston Park Hospital, University of Sheffield
Member	Dr Perminder Tony Singh Dhillon ¹⁷ Bsc, MB BS, FRCP, PhD	Consultant Medical Oncologist, Royal Surrey Hospital, Guildford, Surrey and Hon. Senior Lecturer in Oncology, University of Surrey
Member	Dr Anjum Khan PhD MBChB FRCPATH MRCP	Consultant Haematologist, Leeds Teaching Hospitals NHS Trust
Member	Dr Rebecca Kristeleit BSc MBChB PhD FRCP FRSB	Consultant Medical Oncologist, Guy's and St Thomas' NHS Foundation Trust
Member	Professor Siow Ming Lee PhD FRCP	Professor of Medical Oncology, Consultant Medical Oncologist, University College London Hospital
Member	Dr Debashis Sarker ¹⁸ MBChB PhD FRCP	Reader in Experimental Oncology, King's College London Consultant Medical Oncologist, Guy's, St Thomas' and King's College Hospitals
Member	Dr Ben Uttenthal MA MB BS PhD MRCP FRCPATH	Consultant Haematologist, Cambridge University Hospitals

¹⁶ Reappointed 06/07/2024

¹⁷ Appointed 01/04/2024

¹⁸ Appointed 01/04/2024

Membership of the Paediatric Medicines Expert Advisory Group (PMEAG)

Post	Name and title	Affiliations
Chair	Professor Steven Cunningham MBChB PhD FRCPCH	Professor of Paediatric Respiratory Medicine, University of Edinburgh and Honorary Consultant, Royal Hospital for Children and Young People, NHS Lothian, Edinburgh
Vice Chair	Dr Kathryn Johnson MBChB FRCPCH	Consultant Neonatologist & Research Lead Yorkshire & Humber CRN Children's Specialty Lead Clinical Lead, National Congenital Anomaly and Rare Disease Registration Service, NHSD, Leeds General Infirmary
Lay Member	Dr Jacqueline McMurtrie ¹⁹ BSc (Hons) MSc PhD	
Lay Member	Mrs Rhian Thomas-Turner ²⁰ LLM PG Dip Legal Practice	Research and Development Lead, Noah's Ark Children's Hospital for Wales, Cardiff and Vale University Health Board
Member	Mrs Catrin Barker	Pharmacist, NHS Professionals
Member	Dr Simon B Drysdale ²¹ BSc (Hons) MBBS PgDipPID PhD FRCPCH FHEA	Consultant in Paediatric Infectious Diseases and Immunology, St George's University Hospital NHS Foundation Trust Honorary Senior Lecturer, St George's, University of London
Member	Dr Martin William English BMSc MBChB MD, FRCP(Glas), FRCPCH	Consultant Paediatric Oncologist, Birmingham Women's and Children's Hospital NHS Foundation Trust
Member	Dr Daniel Hawcutt BSc (Hons) MB ChB (Hons) MD MRCPCH	Senior Lecturer Paediatric Clinical Pharmacology, Women's and Children's Health, Institute of Translational Medicine, University of Liverpool
Member	Dr Caroline Jones MB ChB FRCPCH MD	Consultant Paediatric Nephrologist, Alder Hey Children's Hospital NHS Foundation Trust

¹⁹ Reappointed 28/01/2024

²⁰ Reappointed 28/01/2024

²¹ Reappointed 26/09/2024

Member	Dr Ashley Liew MBChB MRCPsych MSc	Consultant Paediatric Neuropsychiatrist, Evelina London Children's Hospital and South London & Maudsley NHS Foundation Trust. Honorary Senior Research Fellow, University of Warwick
Member	Dr Daniel E Lumsden MB/BChir MA Cantab MSc PhD FRCPCH	Consultant Paediatric Neurologist, Evelina London Children's Hospital Adjunct Clinical Senior Lecturer, Department of Perinatal Imaging, King's College London
Member	Dr Rubin Minhas ²² MB ChB MBA	GP Principal
Member	Dr Clare Pain BMBS MSc MRPCH	Consultant Paediatric Rheumatologist, Clinical Lead for Rheumatology Honorary Clinical Lecturer, University of Liverpool Co-Chair of NIHR CRN: children/Versus Arthritis Paediatric Rheumatology Clinical Studies Group Associate Director, UK Experimental Arthritis Treatment Centre for Children (Behcet's and scleroderma workstreams)
Member	Dr Guido Pieles PhD MD	Consultant Congenital Cardiologist Congenital Hear Unit, Bristol Heart Institute
Member	Professor Shirley Price MSc PhD FBTS FRSB ERT FHEA FRSC MBPharmacolSoc	Emerita Professor of Toxicology, University of Surrey Visiting Professor of Toxicology, University of Hertfordshire Honorary Professor of Toxicology, UKHSA
Member	Mrs Julia Taylor MSc BSc	Paediatric Advanced Nurse Practitioner, High Dependency Unit, Alder Hey Children's NHS Foundation Trust.
Member	Dr William John Watkins BSc PhD	Senior Statistician/Lecturer, College of Biomedical & Life Sciences, Cardiff University

²² End of Appointment 14/07/2024

Membership of the Pharmacovigilance Expert Advisory Group (PEAG)

Post	Name and title	Affiliations (if applicable)
Chair	Professor Jamie Coleman MD MA (Med Ed) FRCP FBPhS	Consultant Physician, University Hospitals Birmingham NHS Foundation Trust and Honorary Professor in Clinical Pharmacology and Medical Education, University of Birmingham
Vice Chair	Dr Daniel Hawcutt BSc (Hons) MB ChB (Hons) MD, MRCPCH	Senior Lecturer in Paediatric Clinical Pharmacology, Women's and Children's Health, Institute of Translational Medicine, University of Liverpool
Lay Member	Ms Susan Hunneyball BSc (Hons)	
Lay Member	Dr Malcolm Oswald ²³	Honorary Research Fellow in Law, University of Manchester
Lay Member	Mrs Madeleine Wang ²⁴	
Member	Mrs Alana Adams BPharm (Hons) MSc IP MRPharmS	Principal Pharmacist Medicines Information, advice and Safety, University of Cardiff
Member	Professor Darren Ashcroft BPharm MSc PhD FRPharmS	Professor of Pharmacoepidemiology, Head, Drug Usage and Pharmacy Practice Group, University of Manchester
Member	Professor Ann Daly BA PhD FBPhS	Professor of Pharmacogenetics, Faculty of Medical Sciences, Newcastle University
Member	Professor Richard FitzGerald MD MBChB PhD FRC	CRF Director, NIHR Royal Liverpool and Broadgreen CRF
Member	Professor Patricia McGettigan BSc (Pharm) MD FRCPI FRACP SFHEA FBPhS	Professor of Clinical Pharmacology and Medical Education, Queen Mary University of London; Consultant Physician, Barts Health NHS Trust
Member	Dr Fraz Arif Mir MA FRCP	Consultant Physician, Cambridge University Hospitals NHS Foundation Trust

²³ Appointed 22/03/2024

²⁴ End of Appointment 21/01/2024

Member	Professor Rupert Payne MB ChB PhD MRCGP FRCPE FBPhS FHEA	Professor of Primary Care & Clinical Pharmacology University of Exeter
Member	Dr Nashat Qamar ²⁵ MB ChB MRCGP MSc DRCOG BSc (hons)	PCN Clinical Director and GP Partner, Hall Green Health, Birmingham.
Member	Professor Reecha Sofat MBBS, FRCP, PhD	Breckenridge Chair of Clinical Pharmacology and Therapeutics, University of Liverpool.
Member	Dr Anna Schultze ²⁶ BSc MSc PhD	Assistant Professor in Pharmacoepidemiology, Faculty of Epidemiology and Public Health, London School of Hygiene and Tropical Medicine

²⁵ Appointed 22/03/2024

²⁶ Appointed 22/03/2024

Membership of the Antidepressant Risk Minimisation Expert Working Group (ARMEWG)

Post	Name and title	Affiliations
Chair	Professor Angela Thomas OBE MB BS PhD FRCPE FRCPPath	University of Edinburgh
Lay Member	Ms Susan Hunneyball BSc (Hons)	Member of the Pharmacovigilance Expert Advisory Group (PEAG) and Advisory Board on the Registration of Homeopathic Products (ABRHP)
Lay Member	Ms Linda Pepper BA MA (Education)	Member of the Medicines for Women's Health Expert Advisory Group (MWHEAG) and the Isotretinoin Expert Working Group (IEWG)
Member	Professor Tony Avery OBE	GP and Professor of Primary Health Care, National Clinical Director for Prescribing (NHS England)
Member	Professor Arianna Di Florio MD PhD	Professor of Psychiatry, Cardiff University
Member	Professor Nicol Ferrier	Professor of Psychiatry, Institute of Neuroscience, Newcastle University
Member	Dr Jamie Fraser BSc (Hons) MBChB MRCP	GP Partner, Southside Surgery, Inverness
Member	Ellie Gordon	Royal College of Nursing
Member	Professor David Kessler MD MRCP MRCPsych MBBS BA	Professor of Primary Care, Bristol Medical School, University of Bristol
Member	Professor Glyn Lewis	Professor of Psychiatric Epidemiology, University College London
Member	Dr Barry Miller MB Ch.B FRCA FFPMRCA FCEM	Consultant, Pain Management and Anaesthetics, Bolton NHS Foundation Trust
Member	Professor David G C Owens MD (Hons) FRCP FRCPsych	Professor Emeritus of Clinical Psychiatry, the University of Edinburgh
Member	Mr Peter Pratt	National Specialty Adviser for mental health pharmacy, NHS England
Member	Professor Vanessa Raymont MBChB MSc MRCPsych	Associate Professor, University of Oxford and Honorary Consultant Psychiatrist, Oxford Health NHS Foundation Trust

Member	Dr Aditya Sharma	Consultant Child & Adolescent Psychiatrist/Clinical Lead, Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust
Member	Professor David Taylor FRPharmS FRCPE FRCPsych (Hon)	Director of Pharmacy and Pathology, King's College London
Member	Dr Hoo Kee Tsang BSc(Hons) MB BCh FRCA FFPMRCA	Consultant in Pain Medicine and Anaesthesia, Clinical Director of Pain Services, Liverpool University Hospitals NHS Foundation Trust, member of the Royal College of Anaesthetists and the Faculty of Pain Medicine training and assessment committees
Member	Dr Morris Zwi MBBCh FRCPsych	Honorary Consultant Psychiatrist, South West London & St George's NHS Mental Health Trust

Membership of the CHM's Highly Personalised Medicines Expert Working Group (HPMEWG, formerly Cancer Vaccines EWG)

Post	Name and title	Affiliations
Chair	Professor Sir Munir Pirmohamed MB ChB (Hons) PhD FRCP FRCP (Edin) FBPhS, FFPM (Hon) FMedSci	David Weatherall Chair of Medicine, University of Liverpool, NHS Chair of Pharmacogenetics, Director of the Wolfson Centre for Personalised Medicine, Director of the Centre for Drug Safety Science
Lay Member	Mrs Julia Cons	
Member	Dr Robert Andrews SFHEA FHEA	Senior Lecturer Data Hub at Heath, Cardiff
Member	Dr Colin Brown PhD FRCPPath	Consultant Clinical Scientist -Head of H&I Laboratory Colindale NHS Blood and Transplant
Member	Professor Robert Brown BSc PhD	Emeritus Professor of Translational Oncology, Department of Surgery & Cancer, Imperial College London
Member	Dr Peter Buckle FRSPH, FIEHF, FIEA, C.ErgHF	Principal Research Fellow, NIHR London In Vitro Diagnostics Co-operative Department of Surgery and Cancer, Faculty of Medicine, Imperial College London
Member	Professor Tom Clutton-Brock MBE MB ChB FRCP FRCA FFICM	Director, Medical Devices Testing and Evaluation Centre, Clinical Director, NIHR HealthTech Research Centre in Devices, Digital and Robotics, Chair, NICE Interventional Procedures Advisory Committee, Associate Medical Director, University Hospitals Birmingham NHS Foundation Trust, Professor of Anaesthesia & Intensive Care Medicine, University of Birmingham, Chair of the interim Devices Committee
Member	Professor Jamie Coleman MD MA (Med Ed) FRCP FBPhS	Consultant Physician, University Hospitals Birmingham NHS Foundation Trust and Honorary Professor in Clinical Pharmacology and Medical Education, University of Birmingham
Member	Professor Ann Daly BA PhD FBPhS	Professor of Pharmacogenetics, Faculty of Medical Sciences, Newcastle University

Member	Professor Jon Deeks PhD CStat FMedSci	Professor of Biostatistics, Department of Applied Health Science, College of Medicine and Health, University of Birmingham
Member	Dr Brendan Fish BSc PhD	Director of Biologics & RNA Centre of Excellence
Member	Professor Eric Lim MB ChB MD MSc FRCS(C-Th)	Consultant Thoracic Surgeon, Royal Brompton Hospital, Professor of Thoracic Surgery, Imperial College London
Member	Mr Robert Lowe BPharm FRPharmS	Practising Hospital Pharmacist, Specialist Pharmacy Services - East of England
Member	Dr David Millrine PhD	Translational Immunology Team lead, CRUK Cancer Biomarker Centre, University of Manchester
Member	Professor Christian Ottensmeier MD, PhD, FRCP	Professor of Molecular and Clinical Cancer Medicine, University of Liverpool
Member	Professor Poulam Patel PhD, MBBS, FRCP	Professor of Clinical Oncology, University of Nottingham
Member	Professor Yvonne Perrie BSc PhD	Professor in Drug Delivery within the Strathclyde Institute of Pharmacy and Biomedical Sciences
Member	Professor Shirley Price MSc, PhD, FBTS, FRSB, ERT, FHEA, FRSC, MBPharmacolSoc	Emerita Professor of Toxicology, University of Surrey Visiting Professor of Toxicology, University of Hertfordshire Honorary Professor of Toxicology, UKHSA
Member	Professor Jacqui Shaw BSc PhD	Group Leader and Professor of Translational Cancer Genetics, Leicester University
Member	Professor James Spicer FRCP, PhD	Professor of Experimental Cancer Medicine, King's College London; Consultant in Medical Oncology, Guy's & St Thomas' NHS Foundation Trust
Member	Professor Nigel Stallard BA MSc PhD	Professor of Medical Statistics Director Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry
Member	Professor Kevin M G Taylor BPharm PhD FRPharmS	Emeritus Professor of Clinical Pharmaceutics, UCL School of Pharmacy, London
Member	Dr Robin Thorpe BSc PhD FRCPPath	Retired, Head, Division of Biotherapeutics, National Institute for Biological Standards and Control (NIBSC) & Member of the Clinical Trials, Biologicals & Vaccines Expert Advisory Group (CTBVEAG)

Member	Dr David Turner PhD FRCPPath	H&I Laboratory, Scottish National Blood Transfusion Service, Royal Infirmary of Edinburgh
Member	Professor Marc Turner MB ChB PhD MBA FRCP FRCPPath FRSE	Director, Scottish National Blood Transfusion Service
Member	Professor Christopher Weir BSc MSc PhD FRSS Cstat	Professor of Medical Statistics & Clinical Trials, Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh & Member of Commission on Human Medicines (CHM)
Member	Professor Anthony Williams BSc MSc MRCP, FRCPPath, PhD	Professor of Translational Medicine and Honorary Consultant in Clinical Immunology and Allergy, University of Southampton and University Hospital Southampton NHS Trust
Member	Professor Christina Yap ²⁷ MSci PhD C. Stat	Professor of Clinical Trial Biostatistics, Team Leader in Early Phase and Adaptive Trials Team, ICR-Clinical Trials and Statistics Unit, The Institute of Cancer Research [Cancer UK/ UK CI]
Member	Professor Christopher Yau MA MEng DPhil	Professor of Artificial Intelligence, Nuffield Department of Women's & Reproductive Health, University of Oxford and Health Data Research UK
Member	Professor Ly-Mee Yu BSc MSc DPhil	Professor of Clinical Trials and Biostatistics, Deputy Director Academic of Primary Care Clinical Trials Unit, Nuffield Department of Primary Care Health Sciences, University of Oxford

²⁷ Stepped down 10/09/2024

Membership the Real World Data Expert Working Group (RWD EWG)

Post	Name and title	Affiliations
Chair	Professor Deborah Ashby OBE FMedSci	Interim Dean of the Faculty of Medicine, Imperial College London
Member	Professor Janet Darbyshire CBE MB ChB FMedSci FRCP FFPH FRSS (Hon)	Emeritus Professor of Epidemiology, University College London
Member	Dr J Colin Forfar BSc(Hons) MA(Oxon) MD PhD FRCP FRCPE	Retired Consultant Physician and Cardiologist, John Radcliffe Hospital, Oxford
Member	Professor Peter Hall MB ChB MRCP PhD	Professor and Honorary Consultant in Medical Oncology
Member	Dr Daniel Hawcutt BSc (Hons) MB ChB (Hons) MD MRCPCH	Senior Lecturer in Paediatric Clinical Pharmacology, Women's and Children's Health, Institute of Translational Medicine, University of Liverpool, Member of Pharmacovigilance Expert Advisory Group (PEAG) and Member of Paediatric Medicines Expert Advisory Group (PMEAG)
Member	Professor Sarah Meredith	Professor of Clinical Trials, MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, Invited Expert of the Commission on Human Medicines (CHM)
Member	Professor Sir Munir Pirmohamed MB ChB (Hons) PhD FRCP FRCP (Edin) FBPhS, FFPM (Hon) FMedSci	David Weatherall Chair of Medicine, University of Liverpool, NHS Chair of Pharmacogenetics, Director of the Wolfson Centre for Personalised Medicine, Director of the Centre for Drug Safety Science, Chair of the Commission on Human Medicines (CHM)
Member	Professor Christopher Weir BSc (Hons) PhD MSc FRSS C.Stat	Personal Chair in Medical Statistics and Clinical Trials, Usher Institute, University of Edinburgh

Membership of the Valproate Epigenetics Expert Working Group (VEEWG)

Post	Name and title	Affiliations
Chair	Professor Anthony Williams BSc MSc MRCP, FRCPath, PhD	Professor of Translational Medicine and Honorary Consultant in Clinical Immunology and Allergy, University of Southampton and University Hospital Southampton NHS Trust
Lay Member	Ms Julia Cons	
Member	Professor Robert Brown BSc PhD	Emeritus Professor of Translational Oncology, Department of Surgery & Cancer, Imperial College London
Member	Professor Amanda Drake	Retired, Professor, Centre for Cardiovascular Science The Queen's Medical Research Institute University of Edinburgh
Member	Professor Timothy Gant	Head of the Toxicology Department, Radiation Effects Department Radiation, Chemical & Environmental Hazards
Member	Professor David Hunt MB BChir FRCP PhD	Consultant Neurologist, NHS Lothian Professor of Neuroinflammatory Medicine, University of Edinburgh
Member	Professor Rod Mitchell	Professor of Developmental Endocrinology, Centre for Reproductive Health, University of Edinburgh Honorary Consultant Paediatric Endocrinologist, Royal Hospital for Children and Young People, Edinburgh
Member	Professor Shirley Price MSc, PhD, FBTS, FRSB, ERT, FHEA, FRSC, MBPharmacolSoc	Emerita Professor of Toxicology, University of Surrey Visiting Professor of Toxicology, University of Hertfordshire Honorary Professor of Toxicology, UKHSA
Member	Professor Heather M Wallace PhD FRCPath FRSC FRSB FBTS FBPhS ERT	Professor Emeritus of Biochemical Pharmacology and Toxicology, University of Aberdeen
Member	Member1	Professor at the Human Genetics Unit
Member	Member2	Professor of Developmental Epigenetics. MRC Laboratory of Medical Sciences and Imperial College London, Faculty of Medicine

Membership of the CHM's Valproate Implementation Working Group (VIEWG)

Post	Name and title	Affiliations
Chair	Professor David Hunt MB BChir FRCP PhD	Consultant Neurologist, NHS Lothian Professor of Neuroinflammatory Medicine, University of Edinburgh
Member	Professor Helen Cross	The Prince of Wales's Chair of Childhood Epilepsy, Director UCL Great Ormond Street Institute of Child Health
Member	Professor Naomi Fineberg	Consultant Adult Psychiatrist and Professor of Psychiatry, University of Hertfordshire
Member	Dr Daniel Hawcutt BSc (Hons) MB ChB (Hons) MD MRCPCH	Reader Paediatric Clinical Pharmacology Women's & Children's Health, University of Liverpool. Consultant Paediatric Clinical Pharmacologist (Alder Hey Children's Hospital). Director of Research Alder Hey Children's Hospital and Director of NIHR Alder Hey Clinical Research Facility (CRF)
Member	Mr Tony Jamieson FRPharmS	Patient Safety Specialist & Clinical Improvement Lead. Medicines Safety Improvement Programme, NHS England
Member	Professor Anthony Marson	Professor of Neurology, University of Liverpool, The Walton Centre NHS Foundation Trust, NIHR Senior Investigator
Member	Dr Tejal Mitchell	Consultant Neurologist Subspecialty Lead for Epilepsy, Northwest Anglia NHS Foundation Trust and Cambridge University Hospitals NHS Foundation Trust
Member	Ms Kim Morley ²⁸	Advanced Clinical Nurse/Midwife Practitioner in Epilepsy, Hampshire Hospitals NHS Foundation
Member	Prof Finbar O'Callaghan	Professor of Paediatric Neuroscience, Developmental Neurosciences Dept UCL GOS Institute of Child Health
Member	Professor David G C Owens MD (Hons) FRCP FRCPsych	Professor Emeritus of Clinical Psychiatry, the University of Edinburgh
Member	Dr Vanessa Raymont	Senior Clinical Researcher and Honorary Consultant Psychiatrist, Department of Psychiatry, University of Oxford
Member	Dr Martin Wilson	Consultant Physician in Care of the Elderly, Raigmore Hospital, Inverness

²⁸ Retired in 2024

Member	Member3	Consultant Neurologist
Member	Member4	Consultant Neurologist
Member	Member5	Regional Chief Pharmacist, East of England / National CDAO Lead, Medical Directorate, NHS England
Member	Member6	Specialist in Child and Adolescent psychopharmacology CAMHS Medical Director

ANNEX A - DECLARATION OF INTERESTS

Commission on Human Medicines, Commission's Expert Advisory Groups, Expert Working Groups and ad hoc groups members have declared current personal and non-personal interests in the pharmaceutical industry as follows:

Member	Committee(s)	Interest Type	Company / Organisation / Sponsor	Nature of Interest	Current	Additional Information
Aditya Sharma	NPPEAG, ARMEWG	Personal	NIL	N/A	N/A	
Aditya Sharma	NPPEAG, ARMEWG	Non-Personal	Lundbeck	Unrestricted medical educational grant towards a study	No	
Afzal Mohammed	CPSEAG	Personal	Aston Particle Technologies	Shares, Consultancy	Yes	
Afzal Mohammed	CPSEAG	Non-Personal	Catalent Pharma	Research Grant	Yes	
Afzal Mohammed	CPSEAG	Non-Personal	Colorcon Ltd	Research Grant	No	
Afzal Mohammed	CPSEAG	Non-Personal	MaxBiotech Ltd	Research Grant	Yes	
Afzal Mohammed	CPSEAG	Non-Personal	Proveca Ltd	Research Grant	Yes	

Afzal Mohammed	CPSEAG	Non-Personal	Eye Docs Ltd	Research Grant	Yes	
Afzal Mohammed	CPSEAG	Non-Personal	Quest Healthcare	Research Grant	Yes	
Alana Adams	PEAG	Personal	NIL	N/A	N/A	
Alana Adams	PEAG	Non-Personal	NIL	N/A	N/A	
Amanda Adler	CHM, CDRRA EAG	Personal	NIL	N/A	N/A	
Amanda Adler	CHM, CDRRA EAG	Non-Personal	NIL	N/A	N/A	
Amanda Adler	CHM, CDRRA EAG	Conferences /Scientific Meetings	Lilly	I have declined all honorarium related to this, including indirectly (i.e. to my employing institution). I receive travel support when meeting are face-to-face. methodology – no financial personal gain. No products discussed.	No	I am an academic participant on the steering committee of this trial ('TRIUMPH') for an unlicensed compound.
Amanda Adler	CHM, CDRRA EAG	Additional				I do not accept income from the device or pharmaceutical industry. I work for Oxford University, which does receive support from the pharmaceutical industry.

Amanda Drake	Valproate Epigenetics EWG	Personal	NIL	N/A	N/A	
Amanda Drake	Valproate Epigenetics EWG	Non-Personal	NIL	N/A	N/A	
Amine Boualem	CDRRA EAG	Personal	NIL	N/A	N/A	
Amine Boualem	CDRRA EAG	Non-Personal	NIL	N/A	N/A	
Andrew Freedman	IEAG	Personal	NIL	N/A		
Andrew Freedman	IEAG	Non-Personal	Moderna	One PA of my salary is paid by Health & Care Research Wales to act as Clinical Lead for Infection Vaccine Trials in Wales. This session is reimbursed by Moderna (although my role is not limited to Moderna trials).	Yes	
Andrew Pollard	CTBVEAG	Personal	Shionogi	Consultancy	No	Interest held for 1 day
Andrew Pollard	CTBVEAG	Personal	AstraZeneca	AJP is a contributor to intellectual property licensed by Oxford University Innovation to AstraZeneca	No	
Andrew Pollard	CTBVEAG	Non-Personal	AstraZeneca, GSK, Sanofi	Unrestricted grant for 3 day educational course paid to Oxford University	No	

Andrew Pollard	CTBVEAG	Non-Personal	Astra Zeneca	Research grant to support clinical trials on the COVID19 vaccine	No	
Andrew Pollard	CTBVEAG	Non-Personal	Moderna	Supply of materials by Moderna for use in UK Gov funded research	Yes	
Andrew Pollard	CTBVEAG	Non-Personal	Serum Institute of India	Grant to conduct laboratory studies and clinical trials	Yes	
Andrew Pollard	CTBVEAG	Non-Personal	DHSC	Chair of JCVI	Yes	
Andrew Pollard	CTBVEAG	Non-Personal	WHO	Chair of WHO technical advisory group on Salmonella vaccines	Yes	
Andrew Pollard	CTBVEAG	Additional				Non-commercial Grants from Wellcome and Bill & Melinda Gates Foundation on typhoid and paratyphoid vaccines, Medical Research Council (MRC) on paratyphoid vaccine (with University of Maryland; current); Grant from the Gavi on pneumococcal vaccines in Nepal (2013-2024).
Andrew Pollard	CTBVEAG	Additional				European Commission (EC): Preparing for RSV Immunisation and Surveillance in Europe (PROMISE) on RSV biomarkers (Current). Horizon 2020 grant (DIAMONDS) on fever in children and

			pneumonia (current); EC grant (Innovac4) to develop a Clostridioides difficile challenge model (current);
Andrew Pollard	CTBVEAG	Additional	Grants from Innovate UK to develop plague, Q fever vaccines (current) and Chikungunya/Mayaro Virus vaccines (current).
Andrew Pollard	CTBVEAG	Additional	Grants from Coalition for Epidemic Preparedness Innovations (CEPI) on COVID19 vaccines (2021-2024)
Andrew Pollard	CTBVEAG	Additional	A grant was received by Oxford University from National Institute for Health and Care Research (NIHR) and UK Research and Innovation (UKRI) for work on their COVID-19 vaccine (2020 – 2024)
Andrew Pollard	CTBVEAG	Additional	Oxford University has made a strategic partnership with Coalition for Epidemic Preparedness Innovations (CEPI) in 2023 for the development of vaccines against future outbreaks and pandemics, a role in co-ordination however is not

						receiving any research funding under this agreement.
Andrew Pollard	CTBVEAG	Additional				Chair of DHSC's Joint Committee on Vaccination and Immunisation (Unpaid)
Andrew Pollard	CTBVEAG	Additional				Member of WHO's SAGE until 2022 (Unpaid)
Andrew Pollard	CTBVEAG	Additional				Chair of WHO's Salmonella TAG until end of 2024 (Unpaid)
Andrew Pollard	CTBVEAG	Additional				Grant from Bill & Melinda Gates Foundation on evaluating infant schedules (current)
Andrew Rice	NPPEAG	Personal	AstraZeneca, Combi gene	Consultancy	Yes	
Andrew Rice	NPPEAG	Personal	Imperial College	Employee	Yes	
Andrew Rice	NPPEAG	Non-Personal	NIL	N/A		
Andrew Rice	NPPEAG	Additional				ASCR is named as an inventor on patents (neither being actively pursued at present) : • Rice A.S.C., Vandevorde S. and Lambert D.M Methods using N-(2-propenyl)hexadecanamide and related amides to relieve pain.

				WO 2005/079771 • Okuse K. et al Methods of treating pain by inhibition of VGF activity EP13702262.0/ WO2013 110945
Andrew Rice	NPPEAG	Additional		Member Joint Committee on Vaccine and Immunisation-varicella sub-committee – until 15.1.24
Andrew Rice	NPPEAG	Additional		Member of Non Freezing Cold Injury Independent Senior Advisory Committee
Andrew Rice	NPPEAG	Additional		Member of Analgesic Clinical Trial Translation: Innovations, Opportunities, and Networks (ACTION) steering committee (until 2024)
Andrew Rice	NPPEAG	Additional		Grants and studentships - UKRI (Medical Research Council & BBSRC), Versus Arthritis, Alan and Sheila Diamond Trust, Royal British Legion, European Commission, Ministry of Defence, Dr Jennie Gwynn Bequests, The British Pain Society, Royal Society of Medicine
Andrew Rice	NPPEAG	Additional		Honoraria 2024: Hospital for Special Surgery – New York – speakers

						honorarium United Arab Emirates University – reviewers honorarium
Andrew Rice	NPPEAG	Additional				International Association Study of Pain: Executive Committee (President-elect. Became President August 2024). In context of IASP duties - travel and related expenses. Speakers honoraria donated to IASP
Angela Thomas	ARMEWG	Personal	Moderna	Expenses Paid	Yes	
Angela Thomas	ARMEWG	Non- Personal	NIL	N/A	N/A	
Anita Simonds	CDRRA EAG	Personal	Biogen/ACI Clinical	Member of Endpoint Adjudication Committee for BioALS RCT of this drug for motor neurone disease patients with SOD-1 mutation. (no financial interest in drug or trial - my role is to review endpoint events).	No	
Anita Simonds	CDRRA EAG	Non- Personal	NIL	N/A	No	
Anjan Dhar	GRIDEAG	Personal	Takeda UK	Consultancy and advisory role, speaker fees	No	

Anjan Dhar	GRIDEAG	Personal	Janssen UK	Consultancy, advisory and speaker fees	No
Anjan Dhar	GRIDEAG	Personal	Dr Falk Pharma UK	Consultancy, advisory and speaker fees	No
Anjan Dhar	GRIDEAG	Personal	Galapagos	Advisory role, speaker fees	No
Anjan Dhar	GRIDEAG	Personal	Abbvie UK	Speaker fees and Chair	No
Anjan Dhar	GRIDEAG	Personal	BMS	Speaker fees	No
Anjan Dhar	GRIDEAG	Personal	Health Beacon	Speaker fees	No
Anjan Dhar	GRIDEAG	Personal	Tillotts UK	Speaker fees and Chair	No
Anjan Dhar	GRIDEAG	Personal	Pharmacosmos	Speaker fees and hospitality	No
Anjan Dhar	GRIDEAG	Conferences /Scientific Meetings	Abbvie	ECCO 2024: Full registration, travel and accommodation	No
Anjan Dhar	GRIDEAG	Conferences /Scientific Meetings	Johnson and Johnson	United European Gastroenterology Week: Full registration, travel and accommodation	No
Anjan Dhar	GRIDEAG	Non-Personal	NIL	N/A	
Anjum Khan	OHEAG	Personal	Astellas	Fee-paid work	No
Anjum Khan	OHEAG	Personal	Jazz	Fee-paid work	No
Anjum Khan	OHEAG	Personal	AbbVie	Fee-paid work	No

Anjum Khan	OHEAG	Personal	Immedica	Consultancy	No
Anjum Khan	OHEAG	Personal	Incyte	Consultancy	No
Anjum Khan	OHEAG	Personal	Servier	Fee-paid work	No
Anjum Khan	OHEAG	Personal	TCBioPharm	Fee-paid work	No
Anjum Khan	OHEAG	Personal	Synairgen	Consultancy	No
Anjum Khan	OHEAG	Conferences /Scientific Meetings	Jazz	Conference registration, Train Ticket & accommodation	No
Anjum Khan	OHEAG	Non- Personal	Nil	N/A	N/A
Ann Daly	PEAG, HPM EWG	Personal	NIL	N/A	N/A
Ann Daly	PEAG, HPM EWG	Non- Personal	NIL	N/A	N/A
Anna Schultze	PEAG	Personal	NIL	N/A	
Anna Schultze	PEAG	Non- Personal	GSK	A grant for research, as well the studentship of two of my PhD students.	Yes
Anthony Avery	ARMEWG	Personal	NIL	N/A	
Anthony Avery	ARMEWG	Non- Personal	NIL	N/A	
Anthony Avery	ARMEWG	Additional			

National Clinical Director for
Prescribing for NHS England
with clinical responsibility for

promoting initiatives to address the overprescribing of medicines. This includes potential overprescribing of antidepressants, and I have worked on a number of initiatives relating to this including: 1) Advising organisations responsible for providing educational materials for clinicians to update guidance on the appropriate prescription of antidepressants, and how best to help patients withdraw from antidepressants (should they wish to do so); 2) Promoting the appropriate use (and withdrawal) of antidepressants in conference presentations and at educational events, as well as promoting NICE-endorsed alternatives to antidepressant (where appropriate); 3) Promoting the 2023 NHS England document: Optimising personalised care for adults prescribed medicines associated with dependence or withdrawal symptoms: Framework for action for integrated care boards (ICBs) and primary care; 4) Working with the 'Beyond Pills' All Party

						Parliamentary Group to highlight problems associated with overuse of antidepressants and problems with antidepressant withdrawal; 5) Working with the Specialist Pharmacy Service to develop materials to help clinicians better support patients who choose to withdraw from antidepressants.
Anthony Avery	ARMEWG	Additional				A clinical academic at the University of Nottingham. Via the University of Nottingham I have received (and continue to receive) external non-commercial funding to undertake research on the frequency, nature and causes of medication safety problems (mainly in primary care) and interventions aimed at improving medication safety (mainly in primary care).
Anthony Avery	ARMEWG	Additional				NIHR Senior Investigator.
Anthony Avery	ARMEWG	Additional				Practising GP, currently working as a part-salaried GP.
Anthony Williams	PEAG	Personal	NIL	N/A	N/A	

Anthony Williams	PEAG	Non-Personal	NIL	N/A	N/A
Anthony Marson	VIEWG	Personal	NIL	N/A	N/A
Anthony Marson	VIEWG	Non-Personal	GSK and Sanofi	Honoraria for providing lectures paid to University of Liverpool.	No
Anthony Marson	VIEWG	Non-Personal	UCB Pharma	Research grant paid to University of Liverpool	No
Anthony Marson	VIEWG	Non-Personal	Jazz	Fees paid to University of Liverpool for lecture	No
Arianna Di Florio	ARMEWG	Personal	NIL	N/A	N/A
Arianna Di Florio	ARMEWG	Non-Personal	NIL	N/A	N/A
Asha Kasliwal	MWHEAG	Personal	Theramex	Lecture fees and travel expenses received for talk on Women's Health Hubs	No
Asha Kasliwal	MWHEAG	Non-Personal	NIL	N/A	N/A
Ashley Liew	PMEAG	Personal	Flynn Pharma	Speaker fees and expenses	No
Ashley Liew	PMEAG	Personal	Flynn Pharma	Speaker fees and expenses	No
Ashley Liew	PMEAG	Personal	Flynn Pharma	Speaker fees and expenses	No
Ashley Liew	PMEAG	Non-Personal	NIL	N/A	N/A

Ashley Liew	PMEAG	Additional				<p>I do not expect any of the following to impact my partiality but include it as per the Code:</p> <ul style="list-style-type: none"> • I am a Council Member of the British Paediatric Neurology Association, a charity which represents Paediatric Neurologists in the UK) • I am an Executive Committee member of the Child and Adolescent Faculty of the Royal College of Psychiatrists • I am Co-Chair of the Scientific Advisory Committee for the Smith-Magenis Syndrome Foundation, a charity which supports families with a member who has this genetic syndrome
Barbara Conway	PEAG	Personal	NIL	N/A	N/A	
Barbara Conway	PEAG	Conferences /Scientific Meetings	Journal of Woundcare	Wounds Week: Honorarium	No	
Barbara Conway	PEAG	Non-Personal	NIL	N/A	N/A	
Barry Miller	NPP EAG, ARMEWG	Personal	NIL	N/A	N/A	
Barry Miller	NPP EAG, ARMEWG	Non-Personal	NIL	N/A	N/A	

Barry Miller	NPP EAG, ARMEWG	Additional				Elected Board Member of the Faculty of Pain Medicine (FPM) (and former Dean) Current Lead for Medicines Management at the FPM, with specific remit covering the 'Opioids Aware' website a national resource for guidance on opioid prescribing
Ben Forbes	CPSEAG	Personal	NIL	N/A	N/A	
Ben Forbes	CPSEAG	Non-Personal	NIL	N/A	N/A	
Ben Uttenthal	OHEAG	Personal	Gilead (Kite)	Sponsorship for conference attendance, speaker fees, honoraria for advisory board	Yes	
Ben Uttenthal	OHEAG	Personal	Sartorius	Consultancy for product development; potential support for academic programme that I direct	Yes	
Ben Uttenthal	OHEAG	Personal	Swarm Oncology	Consultancy	Yes	
Ben Uttenthal	OHEAG	Personal	Analog Devices	Consultancy	No	
Ben Uttenthal	OHEAG	Personal	Kyverna	Sponsorship for conference attendance, honorarium for advisory board	No	
Ben Uttenthal	OHEAG	Personal	Abbvie	Sponsorship for conference attendance; speaker fees	Yes	

Ben Uttenthal	OHEAG	Personal	Autolus	Sponsorship of clinical trial of which I am principal investigator	Yes
Ben Uttenthal	OHEAG	Conferences /Scientific Meetings	American Society of Haematology annual meeting	Sponsorship of travel / registration fees and provision of accommodation	No
Ben Uttenthal	OHEAG	Conferences /Scientific Meetings	International Conference on Malignant Lymphoma (ICML)	Sponsorship of travel/registration fees and provision of accommodation	No
Ben Uttenthal	OHEAG	Conferences /Scientific Meetings	Summit on Cell Therapy in Autoimmune Disease	Sponsorship of travel/registration fees and provision of accommodation	No
Ben Uttenthal	OHEAG	Non-Personal	Autolus	Sponsorship of clinical trial of which I am principal investigator	Yes
Brendan Fish	HPM EWG	Personal	GSK, Haeon	Shares	Yes
Brendan Fish	HPM EWG	Non-Personal	NIL	N/A	N/A
Brendan Fish	HPM EWG	Additional			

I work for the Centre for Process Innovation, an innovation social enterprise part of the UK Governments High Value Manufacturing Catapult. CPI helps pharma companies to scale up new medicines, develop vaccine production capacity, and navigate the complex

regulatory pathways needed to get to market. My teams work on the unique challenges in designing, developing, and scaling biologic drugs (everything from recombinant proteins to antibodies, VLPs and gene therapies). At our RNA Centre of Excellence (a UK-based open-access facility) we work with a variety of academics, SME's, and the Pharmaceutical Industry on RNA manufacturing solutions and scaling up RNA therapeutics ready to use in clinical trials. CPI's offer is unique because we're agnostic to who we work with and we care about innovation, not profit. We want to develop ground-breaking new products, but they aren't ours to market. We exist purely to help others. If we discover an exciting new way of manufacturing RNA, for example, we will let anyone use it in their own processes.

Brian Angus

IEAG

Personal

NIL

N/A

N/A

Brian Angus	IEAG	Non-Personal	NIL	N/A	N/A
Caitlin Dean	MWHEAG	Personal	NIL	N/A	N/A
Caitlin Dean	MWHEAG	Non-Personal	NIL	N/A	N/A
Member6	VIEWG	Personal	NIL	N/A	N/A
Member6	VIEWG	Non-Personal	NIL	N/A	N/A
Caroline Jones	PMEAG	Personal	NIL	N/A	N/A
Caroline Jones	PMEAG	Non-Personal	Traverse Therapeutics	Co-Investigator on research trial at Alder Hey Children's Hospital	No
Caroline Jones	PMEAG	Non-Personal	Astellis	PI on research trial at AHCH	No
Catrin Barker	PMEAG	Personal	NIL	N/A	N/A
Catrin Barker	PMEAG	Non-Personal	NIL	N/A	N/A
Celia Moss	GRIDEAG	Personal	NIL	N/A	N/A
Celia Moss	GRIDEAG	Non-Personal	NIL	N/A	N/A
Celia Moss	GRIDEAG	Additional			Trustee of National Eczema Society Member of British Association of Dermatologists

Chris Goldring	CTBVEAG	Personal	NIL	N/A	N/A
Chris Goldring	CTBVEAG	Non-Personal	Pfizer, MSD, Roche, Eli Lilly, Novartis, Janssen, Sanofi-Aventis	Grant on Innovative Medicines Initiative Project	Yes
Chris Goldring	CTBVEAG	Non-Personal	RedX Pharma	Consultancy paid into University of Liverpool research account	Yes
Chris Goldring	CTBVEAG	Non-Personal	Merck	Grant. Completion of research papers associated with this work.	No
Chris Goldring	CTBVEAG	Non-Personal	Eli Lilly, Abbvie, Servier, Sanofi-Aventis, AZ, GSK, Janssen, Orion, B.I.	Grant. Completion of research papers associated with this work.	No
Christian Ottensmeier	HPMEWG	Personal	Neuvogen	Consultancy	Yes
Christian Ottensmeier	HPMEWG	Personal	Transgene	Consultancy	Yes
Christian Ottensmeier	HPMEWG	Non-Personal	Transgene	CI of clinical trial	Yes
Christian Ottensmeier	HPMEWG	Non-Personal	Scancell	CI of clinical trial	Yes
Christian Ottensmeier	HPMEWG	Non-Personal	BioNtech	CI of clinical trial	Yes

Christian Ottensmeier	HPMEWG	Non-Personal	Akamis bio	CI of clinical trial	Yes
Christian Ottensmeier	HPMEWG	Non-Personal	Bristol Myers Squibb	Research funding	
Christian Ottensmeier	HPMEWG	Non-Personal	Touchlight Genetics	Discussions of trial development / grant	Yes
Christian Ottensmeier	HPMEWG	Non-Personal	Merck	Clinical trials funding, PI role and TMG role	Yes
Christian Ottensmeier	HPMEWG	Non-Personal	Verastem	Clinical trials funding, , PI role and TMG role	Yes
Christian Ottensmeier	HPMEWG	Non-Personal	Lineage therapeutics	Trial funding to Southampton University hospitals (trial sponsored by CRUK)	Yes
Christina Yap	CTBVEAG, HPMEWG	Personal	Faron Pharmaceuticals	Independent Statistical Consultant	No
Christina Yap	CTBVEAG, HPMEWG	Personal	Duke Street	Research grant as statistical methodologist/advisor	Yes
Christina Yap	CTBVEAG, HPMEWG	Personal	Merck	Independent Statistical Consultant; Providing patient-reported outcomes methodology expert advice.	Yes
Christina Yap	CTBVEAG, HPMEWG	Personal	Trogenix	Independent Statistical Consultant	Yes
Christina Yap	CTBVEAG, HPMEWG	Non-Personal	AstraZeneca	Trial grant (where I am a co-investigator)	No

Christina Yap	CTBVEAG, HPMEWG	Non-Personal	Plexxikon	Trial grant (where I am a co-investigator)	No
Christopher Weir	CHM, RWDEWG, HPMEWG	Personal	NIL	N/A	N/A
Christopher Weir	CHM, RWDEWG, HPMEWG	Non-Personal	AB Science	DSMB membership for three trials (in ALS, mastocytosis and progressive MS), plus advice on regulatory submissions, resulting in income to my department	Yes
Christopher Weir	CHM, RWDEWG, HPMEWG	Non-Personal	Eli Lilly	Research grant to institution, on which I am co-applicant	Yes
Christopher Yau	HPMEWG	Personal	NIL	N/A	N/A
Christopher Yau	HPMEWG	Non-Personal	Roche	Roche funded DPhil student to University of Oxford	Yes
Clare Pain	PMEAG	Personal	NIL	N/A	N/A
Clare Pain	PMEAG	Non-Personal	NIL	N/A	N/A
Clare Pain	PMEAG	Additional			

Currently have CTIMPS open at our site with following companies (my role stated):
 Abbvie – site PI for Risankizumab in JIA
 Amgen – UK CI for paediatric Behcet’s trial of apremilast (ongoing)
 Lilly – ixekizumab in JIA – in follow-up (sub-investigator)

						Roche – Obinutuzumab in lupus nephritis (sub-investigator) AstraZeneca – anifrolumab in paediatric lupus (sub-investigator)
Colin Brown	HPMEWG	Personal	NIL	N/A	N/A	
Colin Brown	HPMEWG	Non-Personal	NIL	N/A	N/A	
Colin Forfar	RWDEWG	Personal	NIL	N/A	N/A	
Colin Forfar	RWDEWG	Non-Personal	NIL	N/A	N/A	
Daniel Hawcutt	PEAG, PMEAG, VIEWG	Personal	Steritas	Member of Advisory Panel	Yes	
Daniel Hawcutt	PEAG, PMEAG, VIEWG	Non-Personal	NIL	N/A	N/A	
Daniel Hawcutt	PEAG, PMEAG, VIEWG	Additional				Director of the NIHR Alder Hey Clinical Research Facility – with approximately 50-60 early phase studies ongoing. I do not get paid for this activity – my time is funded via an NIHR award, but the trust I work for (Alder Hey) does get commercial income from these contracts (at the set national NIHR rates). I declare any open studies on similar or

						related products with any relevant agenda items as “non personal non-specific” in any committee where this appears in the agenda.
Daniel Lumsden	PMEAG	Personal	NIL	N/A	N/A	
Daniel Lumsden	PMEAG	Conferences /Scientific Meetings	Taysha	Investigators Meeting Taysha TSHA-102 Gene Therapy: Expenses paid to attend investigators meeting. I am CI for this study in the UK (no fees paid for this role)	No	
Daniel Lumsden	PMEAG	Non-Personal	NIL	N/A	N/A	
Daniel Lumsden	PMEAG	Additional				Immediate family member works for Sanofi as Head of Regulatory Science and Policy, EU/AMEE Region, who receives a salary from Sanofi, and shares in the company as part of remuneration.
Daniel Lumsden	PMEAG	Additional				I am Chief Investigator in the UK for the REVEAL Pediatric Study – Safety and Efficacy of TSHA-102 in Pediatric Females with Rett Syndrome. This study is sponsored by Taysha. I have been CI for this study since MHRA approval was received in

January 2024. This study is ongoing.

Darragh Murnane	CPSEAG	Personal	Adare Pharmaceuticals Inc. (New Jersey, USA)	Consultancy	No
Darragh Murnane	CPSEAG	Personal	Informix Pharma Ltd	Personal, Founder and Director	Yes
Darragh Murnane	CPSEAG	Personal	Merxin Ltd.	Non-specific, Scientific Advisory Board Fees	Yes
Darragh Murnane	CPSEAG	Non-Personal	Fluid Pharma Ltd	Non-personal, University Director and no personal benefit	No
Darragh Murnane	CPSEAG	Non-Personal	AstraZeneca	In-kind support for research project at University of Hertfordshire	No
Darragh Murnane	CPSEAG	Non-Personal	Bespak Ltd.	Funding for collaborative research, 2 PhD projects and consultancy performed through University of Hertfordshire	Yes
Darragh Murnane	CPSEAG	Non-Personal	Capitainer Ab	Sponsored research student at University of Hertfordshire	Yes
Darragh Murnane	CPSEAG	Non-Personal	Chiesi Ltd.	Sponsored PhD Student	No
Darragh Murnane	CPSEAG	Non-Personal	Chiesi Ltd.	Speakers fees paid to Informix Pharma Ltd.	No

Darragh Murnane	CPSEAG	Non-Personal	Philips Respironics	Loaned Equipment at University of Hertfordshire	Yes	
Darragh Murnane	CPSEAG	Conferences /Scientific Meetings	Merxin Ltd.	Hospitality at DDL 2024 conference	No	
Darragh Murnane	CPSEAG	Conferences /Scientific Meetings	Chiesi Ltd	Chiesi Medical Education programme on Inhaler Resistance: Travel expenses for travel to Manchester to present to healthcare practitioners' panel	No	
Darragh Murnane	CPSEAG	Conferences /Scientific Meetings	RDD Online	RDD 2024: Speakers Fees	No	
Darragh Murnane	CPSEAG	Conferences /Scientific Meetings	Merxin Ltd	Hospitality at RDD 2024 conference	No	
Darragh Murnane	CPSEAG	Conferences /Scientific Meetings	Merxin Ltd	SMI.London: Free Speaker Registration	No	
Darragh Murnane	CPSEAG	Additional				Founder of Informix Pharma Ltd. And the current CEO of Wickham Micro Ltd. Board Member of Informix Pharma Ltd. Wickham Micro Ltd. provide contract analytical services to the pharmaceutical industry.

Darren Ashcroft	PEAG	Personal	NIL	N/A	N/A	
Darren Ashcroft	PEAG	Non-Personal	LEO Foundation, Bristol Myers Squibb, Boehringer Ingelheim, Johnson & Johnson (Janssen), Almirall	Research grant to support the development of the Global Psoriasis Atlas	Yes	
David Crundwell	CHM	Personal	NIL	N/A	N/A	
David Crundwell	CHM	Non-Personal	NIL	N/A	N/A	
David Crundwell	CHM	Additional				Chair of NHS Clinical Priorities Advisory Group (CPAG): Three-year term until April 2026
David Dockrell	CHM, IEAG	Personal	NIL	N/A	N/A	
David Dockrell	CHM, IEAG	Non-Personal	Adiso Therapeutics, Inc GlaxoSmithKline Pfizer Inc Chan Zuckerberg Initiative Santerus AG IPInc Intercept Pharmaceuticals inc Gene One Genentech Inc	Sponsorship through grants or other support to investigators	No	Industry companies for whom the academic centre I am director of (Centre for Inflammation Research, University of Edinburgh) has current or recent industry sponsorship through grants or other support to investigators. Other than those outlined these are not direct to me

Stryker
International
Sanofi Pasteur
MSD Limited
GlaxoSmithKline
UCBC UCB
BioPharma Srl
Novartis Pharma
AG
Galecto Biotech
AB
Corin Ltd
Scottish Power
Astra Zeneca
Canon
Gene cell catapult

David Dockrell	CHM, IEAG	Non-Personal	GSK	Access to compounds for research by own personal group and collaborators.	Yes	Commitment to continue to provide further agonist compounds on ongoing MRC Programme grant awarded May 2022. No direct financial benefit, in kind contribution of compounds.
David Dockrell	CHM, IEAG	Non-Personal	Astra Zeneca	Advisor on a research project	Yes	I have reviewed and been included on a research publication-not yet published. No financial benefit Historical link but papers not yet published if company even decide to publish.

David Dockrell	CHM, IEAG	Non-Personal	Moderna, Infex Therapeutics, Cell and Gene Therapy Catapult, PLEX	Access to product pipeline	Yes	I lead an MRC CoRE application. The named companies are named as potential partners in the bid. They state they will share expertise, provide training, advise on potential translational strategies and give access to their product pipeline or in case of PLEX to their AI platform to help the academic partners (Edinburgh, Oxford, Sheffield and Malawi Liverpool Wellcome Trust Centre to develop their findings as host based immunotherapeutics to retune innate immune responses to infection.
David Hunt	CHM, NPPEAG, VIEWG, VEEWG	Personal	NIL	N/A	N/A	
David Hunt	CHM, NPPEAG, VIEWG, VEEWG	Conferences /Scientific Meetings	Portuguese Multiple Sclerosis Study Group	GEEM Spring Meeting (Portugal): Accommodation and travel	No	
David Hunt	CHM, NPPEAG, VIEWG, VEEWG	Non-Personal	NIL	N/A	N/A	
David Hunt	CHM, NPPEAG, VIEWG, VEEWG	Additional				Provided advice to Moderna on safety aspects of clinical trial design (unremunerated).

David Hunt	CHM, NPPEAG, VIEWG, VEEWG	Additional				Spoken at a number of multiple sclerosis meetings which have received sponsorship from the pharmaceutical industry (unremunerated).
David Hunt	CHM, NPPEAG, VIEWG, VEEWG	Additional				Lead NHS multiple sclerosis services within the Anne Rowling Clinic in Edinburgh. The Anne Rowling Clinic is supported by a philanthropic gift from JK Rowling to the University of Edinburgh.
David Kessler	ARMEWG	Personal	NIL	N/A	N/A	
David Kessler	ARMEWG	Non-Personal	NIL	N/A	N/A	
David Millrine	HPMEWG	Personal	NIL	N/A	N/A	
David Millrine	HPMEWG	Non-Personal	NIL	N/A	N/A	
David Moore	CHM	Personal	NIL	N/A	N/A	
David Moore	CHM	Non-Personal	NIL	N/A	N/A	
David Owens	NPPEAG, VIEWG, ARMEWG	Personal	NIL	N/A	N/A	

David Owens	NPPEAG, VIEWG, ARMEWG	Non- Personal	TEVA	NIL – telephone discussion only	No	I had a single telephone conversation with a senior medical advisor to Teva on the general topic of tardive dyskinesia, on which I have authored a text and in relation to which this company has a product being considered for marketing in the UK. No remuneration or other blandishments were offered or sought and I have had no further contact.
David Taylor	ARMEWG	Personal	Janssen-Cilag Ltd	Grant	Yes	
David Taylor	ARMEWG	Personal	Otsuka	Grant	No	
David Taylor	ARMEWG	Personal	Viatrix	Consultancy	Yes	
David Taylor	ARMEWG	Personal	Merck	Consultancy	No	
David Taylor	ARMEWG	Personal	Idorsia	Consultancy	Yes	
David Taylor	ARMEWG	Personal	428 Pharma	Shares	Yes	
David Taylor	ARMEWG	Personal	Myogenes	Shares	Yes	
David Taylor	ARMEWG	Personal	Saladax	Shares	Yes	
David Taylor	ARMEWG	Non- Personal	NIL	N/A	N/A	
David Turner	HPM EWG	Personal	NIL	N/A	N/A	

David Turner	HPM EWG	Non-Personal	NIL	N/A	N/A
Debashis Sarker	OHEAG	Personal	Astra Zeneca	Advisory Board	Yes
Debashis Sarker	OHEAG	Personal	Servier	Invited speaker, advisory board	Yes
Debashis Sarker	OHEAG	Personal	Eisai	Invited speaker, advisory board	Yes
Debashis Sarker	OHEAG	Personal	Ipsen	Invited speaker	Yes
Debashis Sarker	OHEAG	Conferences /Scientific Meetings	Ipsen	European NET Society (ENETS) Annual Meeting: Travel, conference and hotel expenses	No
Debashis Sarker	OHEAG	Conferences /Scientific Meetings	Servier	European Society Medical Oncology Annual Meeting: Travel, conference and hotel expenses	No
Debashis Sarker	OHEAG	Non-Personal	UCB Biopharma	Research fellowship grants to KCL	Yes
Deborah Ashby	RWDEWG	Personal	NIL	N/A	
Deborah Ashby	RWDEWG	Non-Personal	NIL	N/A	
Deborah Ashby	RWDEWG	Additional			

From January 2024, I have been Dean of the Faculty of Medicine at Imperial College London. Some staff hold grants, consultancies etc but I have had no direct involvement in those.

Diana Wellesley	MWHEAG	Personal	NIL	N/A	N/A
Diana Wellesley	MWHEAG	Non-Personal	NIL	N/A	N/A
Ellie Gordon	CHM, ARMEWG	Personal	NIL	N/A	N/A
Ellie Gordon	CHM, ARMEWG	Non-Personal	NIL	N/A	N/A
Eric Lim	HPMEWG	Personal	AstraZeneca	Consultancy, advisory board, fee paid education, NICE expert advisor	No
Eric Lim	HPMEWG	Personal	Boehringer Ingelheim	Consultancy	No
Eric Lim	HPMEWG	Personal	Medela	Consultancy, advisory board, fee paid education	No
Eric Lim	HPMEWG	Personal	Beigene	Consultancy	No
Eric Lim	HPMEWG	Personal	Roche	Consultancy, advisory board, fee paid education	No
Eric Lim	HPMEWG	Personal	BMS	Consultancy, advisory board, fee paid education	No
Eric Lim	HPMEWG	Personal	Merck Sharp and Dohme	Advisory board	No
Eric Lim	HPMEWG	Non-Personal	AstraZeneca	Unrestricted grant	No

Eric Lim	HPMEWG	Non-Personal	Lilly	Unrestricted grant	No
Eric Lim	HPMEWG	Non-Personal	Bayer	Unrestricted grant	No
Eric Lim	HPMEWG	Non-Personal	Boehringer Ingelheim	Unrestricted grant	No
Eric Lim	HPMEWG	Non-Personal	Takeda	Unrestricted grant	No
Eric Lim	HPMEWG	Non-Personal	Roche	Unrestricted grant	No
Farzin Farzaneh	CTBVEAG	Personal	Apterna	Consultancy	Yes
Farzin Farzaneh	CTBVEAG	Personal	Autolus, UK	Shares	No
Farzin Farzaneh	CTBVEAG	Personal	VacV Therapeutics	Consultant	Yes
Farzin Farzaneh	CTBVEAG	Personal	Dawn Therapeutics	Consultancy and Shares	Yes
Farzin Farzaneh	CTBVEAG	Personal	ViroCell Biologics Ltd	Appointed as the Chief Scientific Officer. I am also a Co-Founder and Shareholder	Yes
Farzin Farzaneh	CTBVEAG	Personal	King's College London	Part-time Professor of Molecular Medicine	Yes
Farzin Farzaneh	CTBVEAG	Personal	Guys Hospital NHS Trust	Qualified Person	Yes

Farzin Farzaneh	CTBVEAG	Personal	University of Dresden, Germany	Trans-Campus Professor of Molecular Medicine, in partnership with King's College London	No
Farzin Farzaneh	CTBVEAG	Personal	Great Ormond Street Hospital NHS Trust	Qualified Person	Yes
Farzin Farzaneh	CTBVEAG	Personal	Imperial College London	Visiting Professor of Molecular Medicine	Yes
Farzin Farzaneh	CTBVEAG	Personal	University College London	Honorary Professor of Molecular Medicine	Yes
Farzin Farzaneh	CTBVEAG	Non-Personal	NIL	N/A	N/A
Federico Brucoli	CPSEAG	Personal	NIL	N/A	N/A
Federico Brucoli	CPSEAG	Non-Personal	NIL	N/A	N/A
Fergus Rugg-Gunn	NPPEAG	Personal	NIL	N/A	N/A
Fergus Rugg-Gunn	NPPEAG	Non-Personal	NIL	N/A	N/A
Finbar O'Callaghan	VIEWG	Personal	NIL	N/A	N/A
Finbar O'Callaghan	VIEWG	Non-Personal	NIL	N/A	N/A

Fraz Mir	PEAG	Personal	BNF	Chair of BNF Formulary Committee: Honorarium	Yes
Fraz Mir	PEAG	Conferences /Scientific Meetings	AstraZeneca	Cambridge Medical Seminars Conference: grant and venue for meeting	No
Fraz Mir	PEAG	Non-Personal	NIL	N/A	N/A
Geraint Davies	IEAG	Personal	NIL	N/A	N/A
Geraint Davies	IEAG	Non-Personal	NIL	N/A	N/A
Geraint Davies	IEAG	Additional			

I was the academic co-ordinator of the PreDiCT-TB consortium, a public-private partnership funded by the European Union Innovative Medicines Initiative and the European Federation of Pharmaceutical Industries and Associations. However, though this role involved engagement with industrial partners (GSK, Sanofi, Janssen) in pre-competitive areas of research into TB drug development, these activities were fully supported by public funding from the EU and neither myself nor my research institution received any funding from EFPIA or

from the individual industrial partners.

Geraint Davies IEAG Additional

Since 2017 I have been an academic partner to the PanACEA clinical trials consortium, funded by the European and Developing Countries Clinical Trials Partnership. Though the consortium has involved contact and collaboration with pharmaceutical partners, my role at the University of Liverpool is as a partner without budget supporting the clinical trials site at the College of Medicine in Blantyre, Malawi. Neither myself, the University of Liverpool nor the University of Malawi College of Medicine receive any funding from pharmaceutical collaborators as part of these activities.

Geraint Davies IEAG Additional

Since 2020 I have been an academic partner to the UNITE4TB consortium, a new public-private partnership funded by the European Union Innovative Medicines Initiative and the European Federation of Pharmaceutical Industries

					until 2028. However, though this role involves engagement with industrial partners (GSK, Janssen, Evotech) in pre-competitive areas of research into TB drug development, these activities are fully supported by public funding from the EU and neither myself nor my research institution receive any funding from EFPIA or from the individual industrial partners.
Geraint Davies	IEAG	Additional			I have attended expert advisory meetings relating to TB drug development convened by GSK and Janssen for which I received no payment or benefit (honorarium, expenses, hospitality)
Gerri Mortimore	CHM	Personal	NIL	N/A	N/A
Gerri Mortimore	CHM	Conferences /Scientific Meetings	Mark Allen publishing group (GIN Journal)	Gastrointestinal Nursing conference: one of the speakers on the day as well as invited panel expert. MAG paid Hotel fee and return train fare. No payment was given for speaking as this is recognised as part of my Professional role as associate professor at a HEI.	No

Gerri Mortimore	CHM	Non-Personal	NIL	N/A	N/A
Glyn Lewis	ARMEWG	Personal	ECNP 2023	Travel and accommodation for attending the European College of Neuropsychopharmacology	No
Glyn Lewis	ARMEWG	Personal	Fortitude law	Paid for expert advice to a litigation concerned with paroxetine withdrawal symptoms in relation to GSK	Yes
Glyn Lewis	ARMEWG	Personal	NIHR	Funded as Chief Investigator to investigate pregabalin for treating anxiety in those not responding to antidepressants (PETRA)	Yes
Glyn Lewis	ARMEWG	Personal	NIHR	Funded as chief investigator to investigate sertraline for depressive symptoms in primary care (PANDA RCT)	
Glyn Lewis	ARMEWG	Personal	NIHR	Co-applicant on NIHR grant	Yes
Glyn Lewis	ARMEWG	Personal	NIHR	Chief investigator on NIHR grant	No
Glyn Lewis	ARMEWG	Conferences /Scientific Meetings	NIL	N/A	N/A
Glyn Lewis	ARMEWG	Non-Personal	NIL	N/A	N/A

Guido Pieleles	PMEAG	Personal	Pharmanovia	Consultant advisor in regulatory proceedings	Yes
Guido Pieleles	PMEAG	Personal	Canon Medical Systems	Development of hard and software consultant and lecturer	No
Guido Pieleles	PMEAG	Non-Personal	NIL	N/A	N/A
Hadar Zaman	CPSEAG	Personal	NIL	N/A	N/A
Hadar Zaman	CPSEAG	Non-Personal	NIL	N/A	N/A
Hannah Batchelor	CPSEAG	Personal	NIL	N/A	N/A
Hannah Batchelor	CPSEAG	Non-Personal	UCB	Grant awarded to support a PhD student under my supervision	No
Hannah Batchelor	CPSEAG	Non-Personal	GSK	Grant awarded to support a PhD student under my supervision	Yes
Hassan Kahal	CDRRA EAG	Personal	NIL	N/A	N/A
Hassan Kahal	CDRRA EAG	Non-Personal	NIL	N/A	N/A
Hassan Kahal	CDRRA EAG	Additional			Investigator (principal investigator and sub-investigator) on a number of commercial and non-commercial multi-centre clinical research trials related to obesity and

						diabetes conducted at the Diabetes research centre at North Bristol NHS Trust. Family member works for Novo Nordisk in drug development but this has no impact on my clinical decision making. I received no personal payment, honoraria, or travel support from any pharmaceutical company
Heather Wallace	CHM, VEEWG	Personal	NIL	N/A	N/A	
Heather Wallace	CHM, VEEWG	Non-Personal	NIL	N/A	N/A	
Heather Wallace	CHM, VEEWG	Additional				I am Chair of Medical Research Scotland. We fund PhD studentships, and each studentship has an external partner organisation (EPO). This can be industry or charity. The relationship is between the student, supervisor and university. Medical Research Scotland provides funds to the University who funds the student but has no relationship with the student or the EPO.
Hoo Kee Tsang	NPPEAG, ARMEWG	Personal	NIL	N/A	N/A	

Hoo Kee Tsang	NPPEAG, ARMEWG	Non- Personal	NIL	N/A	N/A	
Jacqueline McMurtrie	PMEAG	Personal	NIL	N/A	N/A	
Jacqueline McMurtrie	PMEAG	Non- Personal	NIL	N/A	N/A	
Jacqueline McMurtrie	PMEAG	Additional		.		Director at WRK Othopedics which is family member's private practice - have no involvement with any pharmaceuticals companies.
Jacqui Shaw	HPMEWG	Personal	Thermofisher	Reagents to support early access programme	Yes	
Jacqui Shaw	HPMEWG	Personal	AstraZeneca	Research grant	No	
Jacqui Shaw	HPMEWG	Personal	Nonacus	Reagents to support product development and validation	Yes	
Jacqui Shaw	HPMEWG	Non- Personal	NIL	N/A	N/A	
James Pitayanukul	GRID EAG	Personal	NIL	N/A	N/A	
James Pitayanukul	GRID EAG	Non- Personal	NIL	N/A	N/A	
James Pitayanukul	GRID EAG	Additional				Treasurer of the National Eczema Society, a charity registered in the UK. I am a

Partner in accountancy firm, P and Co (Partners) LLP. I am a director of three limited companies: P and Co Services Ltd, Eczema Trading Limited and Good UK Properties Limited.

James Spicer	OHEAG, HPMEWG	Personal	Epsilon Ltd, co-founder	Stock ownership	Yes
James Spicer	OHEAG, HPMEWG	Personal	APOBEC Discovery Ltd	Board Membership	Yes
James Spicer	OHEAG, HPMEWG	Personal	Achilles	Reimbursement to my institution for recruitment to clinical trials	Yes
James Spicer	OHEAG, HPMEWG	Personal	Gilead	Reimbursement to my institution for recruitment to clinical trials	Yes
James Spicer	OHEAG, HPMEWG	Personal	IO Biotech	Reimbursement to my institution for recruitment to clinical trials	Yes
James Spicer	OHEAG, HPMEWG	Personal	MSD	Reimbursement to my institution for recruitment to clinical trials	Yes
James Spicer	OHEAG, HPMEWG	Personal	Roche	Reimbursement to my institution for recruitment to clinical trials	Yes
James Spicer	OHEAG, HPMEWG	Personal	RS Oncology	Reimbursement to my institution for recruitment to clinical trials	Yes
James Spicer	OHEAG, HPMEWG	Personal	Starpharma	Reimbursement to my institution for recruitment to clinical trials	Yes

James Spicer	OHEAG, HPMEWG	Personal	Avacta Ltd	Stock ownership	Yes
James Spicer	OHEAG, HPMEWG	Conferences /Scientific Meetings	Starpharma	ASCO Annual Meeting: Assistance with attendance at international meetings	No
James Spicer	OHEAG, HPMEWG	Conferences /Scientific Meetings	RS Oncology	ASCO Annual Meeting: Assistance with attendance at international meetings	No
James Spicer	OHEAG, HPMEWG	Non- Personal	APOBEC Discovery Ltd	Reimbursement to my institution for advisory role	Yes
James Spicer	OHEAG, HPMEWG	Non- Personal	AstraZeneca	Reimbursement to my institution for advisory role	Yes
James Spicer	OHEAG, HPMEWG	Non- Personal	BMS	Reimbursement to my institution for advisory role	Yes
James Spicer	OHEAG, HPMEWG	Non- Personal	Roche	Reimbursement to my institution for advisory role	Yes
James Spicer	OHEAG, HPMEWG	Non- Personal	BioNTech	Reimbursement to my institution for advisory role	Yes
Jamie Coleman	CHM, PEAG, HPMEWG	Personal	NIL	N/A	N/A
Jamie Coleman	CHM, PEAG, HPMEWG	Non- Personal	NIL	N/A	N/A
Jamie Fraser	CHM, ARMEWG	Personal	NIL	N/A	N/A

Jamie Fraser	CHM, ARMEWG	Non-Personal	NIL	N/A	N/A
Janet Brown	OHEAG	Personal	Ipsen	Consultancy, advisory boards, travel support to conference	Yes
Janet Brown	OHEAG	Personal	Eisai	Consultancy, advisory boards	Yes
Janet Brown	OHEAG	Personal	Osteolabs	Consultancy (Fee to my employer)	Yes
Janet Brown	OHEAG	Non-Personal	NIL	N/A	N/A
Janet Darbyshire	RWDEWG	Personal	NIL	N/A	N/A
Janet Darbyshire	RWDEWG	Non-Personal	NIL	N/A	N/A
John Petrie	CDRRA EAG	Personal	Boehringer-Ingelheim	Endpoint Committee for trials (personal fees for Consultancy via University of Glasgow)	Yes
John Petrie	CDRRA EAG	Personal	Merck KGaA	Honorarium for review article commissioned by Diabetes, Obesity and Metabolism for special issue funded by Merck KGAA	No
John Petrie	CDRRA EAG	Personal	Sanofi	Attended Sanofi Advisory Board for expert opinion management	No
John Petrie	CDRRA EAG	Conferences /Scientific Meetings	Sanofi	European Association for the Study of Diabetes: Registration, accommodation, travel	No

John Petrie	CDRRA EAG	Non-Personal	Novo Nordisk	Donation of IMP for investigator-led trial (compassionate due to market supply issues)	Yes	
Jon Deeks	HPMEWG	Personal	NIL	N/A	N/A	
Jon Deeks	HPMEWG	Non-Personal	NIL	N/A	N/A	
Jonathan Lord	MWHEAG	Personal	NIL	N/A	N/A	
Jonathan Lord	MWHEAG	Non-Personal	NIL	N/A	N/A	
Jonathan Lord	MWHEAG	Additional				<p>Additional national roles held (all honorary):</p> <p>Co-chair, Royal College of Obstetricians & Gynaecologists (RCOG) abortion taskforce</p> <p>Chair, quality committee, British Society of Abortion Care Providers (BSACP); co-chair of BSACP until November 2024</p> <p>Past roles and academic work including publications, national guideline committees, development of position statements etc. is given at https://orcid.org/0000-0003-2819-5973.</p>

Julia Cons	CHM, HPMEWG, VEEWG	Personal	NIL	N/A	N/A
Julia Cons	CHM, HPMEWG, VEEWG	Non-Personal	NIL	N/A	N/A
Julia Cons	CHM, HPMEWG, VEEWG	Additional			I am vice chair of the Ministry of Defence Research Ethics Committee. I think a conflict of interests is extremely unlikely to arise. However, if any opportunity were to arise for any perceived conflict, I would absent myself from any discussions.
Julia Cons	CHM, HPMEWG, VEEWG	Additional			I am Independent Chair of NHS England's Individual Funding Request Panel. I see no obvious opportunity for a conflict of interests to arise.
Julia Cons	CHM, HPMEWG, VEEWG	Additional			I chaired the NICE Management of Acne Guideline Committee until. The Guideline published in June 2021 so I see no opportunity for a conflict of interests to arise.
Julia Cons	CHM, HPMEWG, VEEWG	Additional			I was a member and deputy chair of the NICE Self-harm: Assessment, Management and Preventing Recurrence Guideline Committee. The

						Guideline published in July 2022 so I see no opportunity for a conflict of interests to arise.
Julia Cons	CHM, HPMEWG, VEEWG	Additional				I am vice chair, and during 2024 was acting chair of NHS England's Specialised Commissioning Patient and Public Voice Assurance Group. I see no obvious opportunity for a conflict of interests to arise.
Julia Prague	MWHEAG	Personal	AstraZeneca	Immediate family member holds shares	Yes	
Julia Prague	MWHEAG	Personal	Synairgen	Immediate family member holds shares	Yes	
Julia Prague	MWHEAG	Personal	Sareum Holdings	Immediate family member holds shares	Yes	
Julia Prague	MWHEAG	Personal	GSK	Immediate family member holds shares	Yes	
Julia Prague	MWHEAG	Personal	Haleon	Immediate family member holds shares	Yes	
Julia Prague	MWHEAG	Non-Personal	NIL	N/A	N/A	
Julia Prague	MWHEAG	Additional				I am an Associate Editor of Endocrine Related Cancer

Journal (not associated with any financial remuneration)					
Julia Taylor	PMEAG	Personal	NIL	N/A	N/A
Julia Taylor	PMEAG	Non-Personal	NIL	N/A	N/A
Kathryn Johnson	PMEAG	Personal	NIL	N/A	N/A
Kathryn Johnson	PMEAG	Non-Personal	NIL	N/A	N/A
Kenneth Hodson	MWHEAG	Personal	NIL	N/A	N/A
Kenneth Hodson	MWHEAG	Non-Personal	NIL	N/A	N/A
Kevin Taylor	HPMEWG	Personal	NIL	N/A	N/A
Kevin Taylor	HPMEWG	Non-Personal	NIL	N/A	N/A
Kim Morley	VIEWG	Personal	NIL	N/A	N/A
Kim Morley	VIEWG	Non-Personal	NIL	N/A	N/A
Kirstie Shearman	CTBVEAG	Personal	NIL	N/A	N/A
Kirstie Shearman	CTBVEAG	Non-Personal	NIL	N/A	N/A

Laura Magee	MWHEAG	Personal	Nightingale Medical	Shares	Yes	
Laura Magee	MWHEAG	Non-Personal	NIL	N/A	N/A	
Laurie Tomlinson	MWHEAG	Personal	NIL	N/A	N/A	
Laurie Tomlinson	MWHEAG	Non-Personal	NIL	N/A	N/A	
Lim Jones	IEAG	Personal	NIL	N/A	N/A	
Lim Jones	IEAG	Non-Personal	NIL	N/A	N/A	
Linda Pepper	MWHEAG, ARMEWG	Personal	NIL	N/A	N/A	
Linda Pepper	MWHEAG, ARMEWG	Non-Personal	NIL	N/A	N/A	
Linda Pepper	MWHEAG, ARMEWG	Additional				Lay Examiner with RCOG part 3 MRCOG exams A public member of Secure Data Environment with North East + North Cumbria ICB A public governor with Newcastle Hospital NHS Trust
Lisa Brownell	NPPEAG	Personal	NIL	N/A	N/A	
Lisa Brownell	NPPEAG	Non-Personal	NIL	N/A	N/A	

Louis Grandjean	IEAG	Personal	Shionogi	Grant	Yes
Louis Grandjean	IEAG	Personal	Pfizer	Grant	Yes
Louis Grandjean	IEAG	Personal	Advanz	Grant	Yes
Louis Grandjean	IEAG	Personal	Mundipharma	Grant	Yes
Louis Grandjean	IEAG	Conferences /Scientific Meetings	Pfizer	Start Meeting: Support for the meeting, travel for speakers and catering costs	No
Louis Grandjean	IEAG	Non- Personal	NIL	N/A	N/A
Louise Massey	MWHEAG	Personal	NIL	N/A	N/A
Louise Massey	MWHEAG	Non- Personal	NIL	N/A	N/A
Louise Massey	MWHEAG	Additional			
Member4	VIEWG	Personal	NIL	N/A	N/A
Member4	VIEWG	Non- Personal	NIL	N/A	N/A

I was a committee member in the NICE Menopause Guideline 23 update completed in November 2024. Meetings and email exchanges regarding the guideline took place between 1.1.24 and 1.7.24. This guideline is now published and the work complete.

Lucy Mackillop	MWHEAG	Personal	Sensyne Health plc	Shareholder	No	
Lucy Mackillop	MWHEAG	Personal	Oxford University Innovation	Payment for royalties	No	
Lucy Mackillop	MWHEAG	Personal	EMIS group plc	Paid employee and Shareholder	Yes	
Lucy Mackillop	MWHEAG	Non-Personal	NIL	N/A	N/A	
Luigi (Gino) Martini	CPSEAG	Personal	GSK	Shares with GSK and pension	Yes	
Luigi (Gino) Martini	CPSEAG	Personal	GSK, MSD, Becton Dickinson, Pinsent Masons, Knobbe Martin	Own consultancy- Lupa Medical	Yes	Private consultancy owned by member
Luigi (Gino) Martini	CPSEAG	Personal	Bioemolous Ltd	Advise on hypochlorous acid sanitiser	Yes	Private consultancy owned by member
Luigi (Gino) Martini	CPSEAG	Personal	Colltech Labs	Unpaid but minor share holder	Yes	
Luigi (Gino) Martini	CPSEAG	Personal	Biotherapy Services Ltd	Unpaid but minor share holder	Yes	
Luigi (Gino) Martini	CPSEAG	Personal	Altabiome Therapeutics Ltd	Unpaid but share holder	Yes	
Luigi (Gino) Martini	CPSEAG	Personal	Lakes Biosciences Ltd	Unpaid but share holder	Yes	

Luigi (Gino) Martini	CPSEAG	Personal	Nash Therapeutics Ltd	Unpaid but share holder	Yes	
Luigi (Gino) Martini	CPSEAG	Personal	Biosimax Ltd	Unpaid but share holder	Yes	
Luigi (Gino) Martini	CPSEAG	Non-Personal	GSK	Funded 2 PhD case awards	No	
Luigi (Gino) Martini	CPSEAG	Non-Personal	Gamlen Tableting/German Government	Funded fellowships to examine tableting	No	
Luigi (Gino) Martini	CPSEAG	Non-Personal	Dr Reddys	Funded research programme	No	
Luigi (Gino) Martini	CPSEAG	Non-Personal	Saudi Government	Funded PhD award	No	
Luigi (Gino) Martini	CPSEAG	Non-Personal	Mexican Government	Funded PhD award	No	
Luigi (Gino) Martini	CPSEAG	Additional				Immediate family member used to work for GSK, has GSK and SB shares as well as pension.
Ly-Mee Yu	HPMEWG	Personal	NIL	N/A	N/A	
Ly-Mee Yu	HPMEWG	Non-Personal	NIL	N/A	N/A	
Madeleine Wang	PEAG	Personal	NIL	N/A	N/A	

Madeleine Wang	PEAG	Non-Personal	NIL	N/A	N/A
Majella Lane	CPSEAG	Personal	NIL	N/A	N/A
Majella Lane	CPSEAG	Non-Personal	NIL	N/A	N/A
Majella Lane	CPSEAG	Additional			I have established a limited company called Melderm Ltd. The company provides expert witness services for patent matters in the United States.
Malcolm Oswald	PEAG	Personal	NIL	N/A	N/A
Malcolm Oswald	PEAG	Non-Personal	NIL	N/A	N/A
Marc Turner	CHM, CTBVEAG, HPMEWG	Personal	NIL	N/A	N/A
Marc Turner	CHM, CTBVEAG, HPMEWG	Non-Personal	Resolution Therapeutics	SNBTS manufacture for first in human clinical trial.	Yes
Mark Evans	CDRRA EAG	Personal	Abbott Diabetes Care	(1) Speakers fees, (2) sponsorship for Clinical triallist on a multicentre study	No
Mark Evans	CDRRA EAG	Personal	Eli Lilly	Speakers Fees	No
Mark Evans	CDRRA EAG	Personal	Pila Pharma	(1) Advisory board (2) Planned clinical triallist	No
Mark Evans	CDRRA EAG	Personal	Zucara	Advisory Board	No

Mark Evans	CDRRA EAG	Personal	Sanofi	(1) Advisory boards (2) Planned speakers fees	No
Mark Evans	CDRRA EAG	Personal	Vertex	(1) Advisory board	No
Mark Evans	CDRRA EAG	Conferences /Scientific Meetings	Eli Lilly	Travel expenses and speaker's fee as above	Yes
Mark Evans	CDRRA EAG	Non- Personal	Abbott Diabetes Care	Clinical triallist	No
Mark Evans	CDRRA EAG	Non- Personal	NovoNordisk	Sponsored PhD studentship as supervisor	No
Mark Evans	CDRRA EAG	Non- Personal	Lexicon	Planned clinical triallist	No
Martin English	PMEAG	Personal	NIL	N/A	N/A
Martin English	PMEAG	Non- Personal	NIL	N/A	N/A
Martin Wilson	CHM, VIEWG	Personal	NIL	N/A	N/A
Martin Wilson	CHM, VIEWG	Non- Personal	NIL	N/A	N/A
Matthias Schmid	IEAG	Personal	NIL	N/A	N/A
Matthias Schmid	IEAG	Non- Personal	NIL	N/A	N/A

Michael Ardern-Jones	GRIDEAG	Personal	Sanofi-Genzyme	Consultancy, Advisory board fees, Conference attendance, Speaker fees	Yes
Michael Ardern-Jones	GRIDEAG	Personal	Leo Pharma	Consultancy, Advisory board fees, Conference attendance, Speaker fees	Yes
Michael Ardern-Jones	GRIDEAG	Personal	AbbVie	Consultancy, Advisory board fees, Conference attendance, Speaker fees	Yes
Michael Ardern-Jones	GRIDEAG	Personal	Pfizer	Consultancy, Advisory board fees, Conference attendance, Speaker fees	Yes
Michael Ardern-Jones	GRIDEAG	Personal	Lilly	Consultancy, Advisory board fees	Yes
Michael Ardern-Jones	GRIDEAG	Personal	J&J (including Janssen)	Consultancy, Advisory board fees, Conference attendance, Speaker fees	Yes
Michael Ardern-Jones	GRIDEAG	Personal	Almirall	Consultancy, Advisory board fees, Conference attendance, Speaker fees	Yes
Michael Ardern-Jones	GRIDEAG	Personal	Galderma	Consultancy, Advisory board fees, Conference attendance, Speaker fees	Yes
Michael Ardern-Jones	GRIDEAG	Personal	Novartis	Consultancy, Advisory board fees, Conference attendance, Speaker fees	Yes

Michael Ardern-Jones	GRIDEAG	Personal	Regeneron	Consultancy, Advisory board fees, Conference attendance, Speaker fees	Yes
Michael Ardern-Jones	GRIDEAG	Conferences /Scientific Meetings	Sanofi-Genzyme	Consultancy, Advisory board fees, Conference attendance, Speaker fees	Yes
Michael Ardern-Jones	GRIDEAG	Conferences /Scientific Meetings	Leo Pharma	Consultancy, Advisory board fees, Conference attendance, Speaker fees	Yes
Michael Ardern-Jones	GRIDEAG	Conferences /Scientific Meetings	AbbVie	Consultancy, Advisory board fees, Conference attendance, Speaker fees	Yes
Michael Ardern-Jones	GRIDEAG	Conferences /Scientific Meetings	Pfizer	Consultancy, Advisory board fees, Conference attendance, Speaker fees	Yes
Michael Ardern-Jones	GRIDEAG	Conferences /Scientific Meetings	Lilly	Consultancy, Advisory board fees	Yes
Michael Ardern-Jones	GRIDEAG	Conferences /Scientific Meetings	J&J (including Janssen)	Consultancy, Advisory board fees, Conference attendance, Speaker fees	Yes
Michael Ardern-Jones	GRIDEAG	Conferences /Scientific Meetings	Almirall	Consultancy, Advisory board fees, Conference attendance, Speaker fees	Yes
Michael Ardern-Jones	GRIDEAG	Conferences /Scientific Meetings	Galderma	Consultancy, Advisory board fees, Conference attendance, Speaker fees	Yes

Michael Ardern-Jones	GRIDEAG	Conferences /Scientific Meetings	Novartis	Consultancy, Advisory board fees, Conference attendance, Speaker fees	Yes
Michael Ardern-Jones	GRIDEAG	Conferences /Scientific Meetings	Regeneron	consultancy, Advisory board fees, Conference attendance, Speaker fees	Yes
Michael Ardern-Jones	GRIDEAG	Non-Personal	Ducentis	UoS collaboration research	Yes
Michael Ardern-Jones	GRIDEAG	Non-Personal	Almirall	UHS Commercial clinical trial	Yes
Michael Ardern-Jones	GRIDEAG	Non-Personal	Abbvie	UHS Commercial clinical trial	Yes
Michael Ardern-Jones	GRIDEAG	Non-Personal	Leo Pharma	UHS Commercial clinical trial	Yes
Michael Ardern-Jones	GRIDEAG	Non-Personal	Leo Pharma	UHS Commercial clinical trial	Yes
Michael Ardern-Jones	GRIDEAG	Non-Personal	Amgen	UHS Commercial clinical trial	Yes
Michael Ardern-Jones	GRIDEAG	Non-Personal	Sanofi	UoS collaboration research, UHS Commercial Trial	Yes
Michael Ardern-Jones	GRIDEAG	Non-Personal	Pfizer	UoS collaboration research	Yes
Michael Ardern-Jones	GRIDEAG	Additional			

Biotechnology and Biological Sciences Research Council
iCASE industrial studentships

						have been funded at my institution with Unilever. I supervised PhDs. Unilever is a consumer goods manufacturer, with an interest in skin science.
Michael Ardern-Jones	GRIDEAG	Additional				I have collaborated with Emblation (unpaid), and have received small donations towards my research programme.
Michael Brown	IEAG	Personal	NIL	N/A	N/A	
Michael Brown	IEAG	Non-Personal	GSK	The Infection Division at UCLH for which I am DCD, received funds for recruitment of patients into the LUNAR SARS-CoV-2 variant monitoring study. I was local PI	No	
Michael Brown	IEAG	Non-Personal	AstraZeneca	The Infection Division at UCLH for which I am DCD, received funds for recruitment of patients into the TILIA study of this anti-IL33 drug. I am local PI	Yes	
Michael Brown	IEAG	Non-Personal	Gilead	The Infection Division at UCLH for which I am DCD, received funds for recruitment of patients into the inpatient and outpatient remdesivir trials. I was local PI for 3 trials and UK CI for one trial	Yes	

Michael Steiner	CDRRA EAG	Personal	NIL	N/A	N/A
Michael Steiner	CDRRA EAG	Conferences /Scientific Meetings	AstraZeneca	Long term conditions conference: Expenses to attend conference only	No
Michael Steiner	CDRRA EAG	Non-Personal	NIL	N/A	N/A
Morris Zwi	ARMEWG	Personal	NIL	N/A	N/A
Morris Zwi	Morris Zwi	Non-Personal	NIL	N/A	N/A
Munir Pirmohamed	CHM, HPMEWG, RWD EWG	Personal	NIL	N/A	N/A
Munir Pirmohamed	CHM, HPMEWG, RWD EWG	Non-Personal	Astra Zeneca	Research grant to University of Liverpool (UoL), University of Manchester (UoM), University of Glasgow (UoG) and Queen Mary University London (QMUL) to support clinical fellowships jointly with UK Medical Research Council (MRC)	Yes
Munir Pirmohamed	CHM, HPMEWG, RWD EWG	Non-Personal	Eli Lilly	Research grant to Universities of Liverpool (UoL) and Manchester (UoM) to support clinical training fellowships jointly with UK Medical Research Council (MRC)	Yes
Munir Pirmohamed	CHM, HPMEWG, RWD EWG	Non-Personal	Novartis	Research grant to UoL and UoM to support clinical training fellowships jointly with MRC	Yes

Munir Pirmohamed	CHM, HPMEWG, RWD EWG	Non-Personal	Roche	Research grant to UoL and UoM to support clinical training fellowships jointly with MRC	Yes
Munir Pirmohamed	CHM, HPMEWG, RWD EWG	Non-Personal	Closed Loop Medicine	Sharing of data on oral anticoagulants – no funding provided	Yes
Munir Pirmohamed	CHM, HPMEWG, RWD EWG	Non-Personal	UCB Pharma	Research grant to UoL and UoM to support clinical training fellowships jointly with MRC	Yes
Munir Pirmohamed	CHM, HPMEWG, RWD EWG	Non-Personal	GSK	Research grant to University of Liverpool (UoL), University of Manchester (UoM), University of Glasgow (UoG) and Queen Mary University London (QMUL) to support clinical fellowships jointly with UK Medical Research Council (MRC)	Yes
Munir Pirmohamed	CHM, HPMEWG, RWD EWG	Non-Personal	Optum	Research grant to University of Liverpool (UoL), University of Manchester (UoM), University of Glasgow (UoG) and Queen Mary University London (QMUL) to support clinical fellowships jointly with UK Medical Research Council (MRC)	Yes
Munir Pirmohamed	CHM, HPMEWG, RWD EWG	Non-Personal	Hammersmith Medicines Research	Research grant to University of Liverpool (UoL), University of Manchester (UoM), University of Glasgow (UoG) and Queen Mary University London (QMUL) to	Yes

support clinical fellowships jointly
with UK Medical Research Council
(MRC)

Munir Pirmohamed	CHM, HPMEWG, RWD EWG	Additional
---------------------	-------------------------	------------

I am part of the IMI Consortium called ARDAT (<https://ardat.org/>). As is well known, this is partnership funding for research through the EU Commission, with academic partners like myself receiving funding via the EU (to the University of Liverpool), while Industry partners provide their expertise as an in-kind contribution. The companies involved in the IMI programme are:
Pfizer/Bayer/Janssen/Pharmaceuticals NV /Lonza AG
/Novartis /Novo Nordisk
/Sanofi-Aventis /Spark Therapeutics, Inc /Takeda Pharmaceuticals International AG /Viscofan SA /Astellas Pharma Europe BV /Roche
These are declared as NP/NS when any of their products come up on the agenda.

Munir Pirmohamed	CHM, HPMEWG, RWD EWG	Additional
---------------------	-------------------------	------------

I have been appointed as Chair of the Prix Galien UK prize awarding committee from September 2023.

Munir Pirmohamed	CHM, HPMEWG, RWD EWG	Additional				I am a Medical Trustee for the British Heart Foundation, and a member of the governing council of the Medical Research Council. I was President of the Association of Physicians until May 2024. I have also advised the Qatar Precision Health Initiative and the Bosch Health Foundation on research related to personalised medicine and pharmacogenomics.
Naomi Fineberg	NPPEAG, VIEWG	Personal	NIL	N/A		N/A
Naomi Fineberg	NPPEAG, VIEWG	Conferences /Scientific Meetings	European College of Neuropsychopharmacology Annual Congress	Expenses		No
Naomi Fineberg	NPPEAG, VIEWG	Conferences /Scientific Meetings	British Association for Psychopharmacology Annual Summer Meeting	Expenses		No
Naomi Fineberg	NPPEAG, VIEWG	Conferences /Scientific Meetings	British Association for Psychopharmacology Masterclass	Expenses		No

Naomi Fineberg	NPPEAG, VIEWG	Conferences /Scientific Meetings	International College of Neuropsychopharmacology Annual Congress	Expenses	No
Naomi Fineberg	NPPEAG, VIEWG	Conferences /Scientific Meetings	Portuguese Society of Psychiatry and Mental Health	Expenses	No
Naomi Fineberg	NPPEAG, VIEWG	Non-Personal	Biohaven	Corporate membership fees were paid to the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS), a medical charity, of which I am the secretary	No
Naomi Fineberg	NPPEAG, VIEWG	Non-Personal	Compass Pathways	The company provided the drug for a research project i had a research role in	No
Naomi Fineberg	NPPEAG, VIEWG	Additional			

I work as a clinical lead of an NHS England service providing pharmacological treatment for obsessive compulsive disorders. I act as an unpaid medical adviser and trustee to national consumer charities for OCD and related disorders. I co-chair the World Psychiatric Association scientific section on anxiety, OCD and related disorders. I have contributed to the current

British Association For Psychopharmacology (BAP) treatment guidelines for anxiety disorders (2014) and the NICE treatment guidelines including the most recent update (2013). I chair the external review board of the European College Of Neuropsychopharmacology (ECNP). I am secretary of the International College Of Obsessive-Compulsive Spectrum Disorders (ICOCS), which has received corporate membership fees from Biohaven. I have received research grants

Naomi Fineberg NPPEAG, VIEWG Additional

From the UKRI, NIHR and Horizon Europe. I receive an honorarium from Elsevier for editorial duties for the journal comprehensive psychiatry. I am a board member of the consumer charity Orchard (registered charity no: 1174480). I have received reimbursement for personal expenses for giving lectures at national and international meetings of various academic bodies in non-industry sponsored symposia.

Nashat Qamar	PEAG	Personal	NIL	N/A	N/A
Nashat Qamar	PEAG	Non-Personal	NIL	N/A	N/A
Nicol Ferrier	ARMEWG	Personal	NIL	N/A	N/A
Nicol Ferrier	ARMEWG	Non-Personal	NIL	N/A	N/A
Nidhi Sofat	GRIDEAG	Personal	NIL	N/A	N/A
Nidhi Sofat	GRIDEAG	Non-Personal	NIL	N/A	N/A
Nigel Stallard	HPMEWG	Personal	NIL	N/A	N/A
Nigel Stallard	HPMEWG	Non-Personal	Novartis	Support for icase PhD studentship	No
Nigel Stallard	HPMEWG	Non-Personal	Janssen	Support for icase PhD studentship	No
Nikoletta Fotaki	CPSEAG	Personal	NIL	NIL	N/A
Nikoletta Fotaki	CPSEAG	Non-Personal	NIL	NIL	N/A
Nikoletta Fotaki	CPSEAG	Additional			

Director of Dr Fotaki
BioPharm Consulting (The
Registrar of Companies for
England and Wales- Company
number: 13238377).

Patricia McGettigan	PEAG	Personal	NIL	N/A	N/A
Patricia McGettigan	PEAG	Non-Personal	NIL	N/A	N/A
Patricia McGettigan	PEAG	Additional			I am an Independent Expert member of the European Medicines Agency Pharmacovigilance Risk Assessment Committee
Patrick Holmes	CDRRA EAG	Personal	Daichii-Sankyo	Speaker Fees	Yes
Patrick Holmes	CDRRA EAG	Personal	Boehringer Ingelheim	Speaker Fees	No
Patrick Holmes	CDRRA EAG	Personal	Abbott	Speaker Fee and consultancy fee	No
Patrick Holmes	CDRRA EAG	Personal	Eli Lilly	Speaker Fees	No
Patrick Holmes	CDRRA EAG	Personal	NovoNordisk	Consultancy Fee	No
Patrick Holmes	CDRRA EAG	Personal	AstraZeneca	Speaker Fees	No
Patrick Holmes	CDRRA EAG	Personal	Dexcom	Speaker Fees	No
Patrick Holmes	CDRRA EAG	Non-Personal	NIL	N/A	N/A
Patrick Mark	CDRRA EAG	Personal	AstraZeneca	Consultancy	No
Patrick Mark	CDRRA EAG	Personal	Vifor	Lecture Fee	No

Patrick Mark	CDRRA EAG	Personal	AstraZeneca	Clinical Trial Steering Committee, research funding	No
Patrick Mark	CDRRA EAG	Personal	Novartis	Trial End Point Committee (blinded)	No
Patrick Mark	CDRRA EAG	Personal	Boehringer Ingelheim	Lecture Fee	No
Patrick Mark	CDRRA EAG	Non-Personal	NIL	N/A	N/A
Paul Dargan	CHM	Personal	NIL	N/A	N/A
Paul Dargan	CHM	Non-Personal	Moderna	PI within my hospital for COVID-19 vaccine study. All funding for this study came to my hospital.	No
Paul Dargan	CHM	Non-Personal	AstraZeneca	I am PI within my hospital for COVID-19 Study: A Phase I/III Randomized, Double-blind Study. All funding from this study comes to my hospital	Yes
Paul Dargan	CHM	Non-Personal	Janssen	I am the PI within my hospital for the vaccine study. All funding for this study comes to my hospital.	Yes
Paul Dargan	CHM	Non-Personal	Atea	I was the UK CI for the Atea Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety in High-Risk Outpatients with COVID-19. All funding for this study came to my hospital.	No

Paul Dargan CHM Additional

Chair of the Royal College of Emergency Medicine and National Poisons Information Service Antidote Guidelines Group which oversees advice to hospitals in England for the stocking of antidotes; I have Chaired this group since 2008. This group provides advice on the amount of antidote to be stocked by hospitals and the time-frame that the antidotes should be available. The advice is based on the published literature and there is no liaison with the pharmaceutical industry in relation to the guidance published by this group.

Paul Dargan CHM Additional

EAPCCT: I am President of the European Association of Poisons Control Centres and Clinical Toxicologists (EAPCCT: <http://www.eapcct.org/>) from May 2024 to May 2025. The EAPCCT is the European Clinical Toxicology Society and its main role is to organise the annual European Toxicology Conference “with the specific goal of advancing knowledge and understanding

						of the diagnosis and treatment of all forms of poisoning”.
Paul Dargan	CHM	Additional				I am an expert adviser on clinical toxicology to the World Health Organisation – this has predominantly involved advising on issues in relation to lead and mercury poisoning. In recent years I have contributed to WHO monographs and guidelines for lead and mercury poisoning.
Paul Dargan	CHM	Additional				I am on the Senior Editorial Board of Clinical Toxicology and the International Editorial Board of British Journal of Clinical Pharmacology.
Perminder Tony Singh Dhillon	OHEAG	Personal	Mount Alvernia PET CT Limited	Shares	Yes	
Perminder Tony Singh Dhillon	OHEAG	Conferences /Scientific Meetings	Takeda	ESMO GI: Funding including flights, accommodation and congress fees	No	
Perminder Tony Singh Dhillon	OHEAG	Conferences /Scientific Meetings	Servier	ESMO: Funding including flights, accommodation and congress fees	No	
Perminder Tony Singh Dhillon	OHEAG	Non-Personal	NIL	N/A	N/A	

Peter Buckle	HPMEWG	Personal	NIL	N/A	N/A
Peter Buckle	HPMEWG	Non-Personal	NIL	N/A	N/A
Peter Hall	RWDEWG	Personal	NIL	N/A	N/A
Peter Hall	RWDEWG	Non-Personal	AstraZeneca	Received Institutional research funding	No
Peter Hall	RWDEWG	Non-Personal	Eisai	Received Institutional research funding	No
Peter Hall	RWDEWG	Non-Personal	Roche	Received Institutional research funding	No
Peter Hall	RWDEWG	Non-Personal	Lilly	Received Institutional research funding	No
Peter Hall	RWDEWG	Non-Personal	Abbvie	Received Institutional research funding	No
Peter Hall	RWDEWG	Non-Personal	Novartis	Received Institutional research funding	No
Peter Hall	RWDEWG	Non-Personal	MSD	Received Institutional research funding	No
Peter Hall	RWDEWG	Non-Personal	Gilead	Received Institutional research funding	No
Peter Hall	RWDEWG	Non-Personal	Sanofi	Received Institutional research funding	No

Peter Hall	RWDEWG	Non-Personal	SeaGen	Received Institutional research funding	No
Peter Hall	RWDEWG	Non-Personal	DxCover	Received Institutional research funding	No
Peter Pratt	ARMEWG	Personal	NIL	N/A	N/A
Peter Pratt	ARMEWG	Non-Personal	NIL	N/A	N/A
Member2	VEEWG	Personal	NIL	N/A	N/A
Member2	VEEWG	Non-Personal	NIL	N/A	N/A
Philip Hannaford	MWHEAG	Personal	NIL	N/A	N/A
Philip Hannaford	MWHEAG	Non-Personal	NIL	N/A	N/A
Poulam Patel	CHM, OHEAG, HPMEWG	Personal	NIL	N/A	N/A
Poulam Patel	CHM, OHEAG, HPMEWG	Non-Personal	NIL	N/A	N/A
Poulam Patel	CHM, OHEAG, HPMEWG	Additional			

I am a co-investigator on an Innovate UK research grant led by University of Nottingham with the SME's, Aqdot and Centillion as co-investigators

Ravishankar Sargur	GRIDEAG	Personal	NIL	N/A	N/A
Ravishankar Sargur	GRIDEAG	Non-Personal	NIL	N/A	N/A
Rebecca Kristeleit	OHEAG	Personal	Basilea	Consultancy	Yes
Rebecca Kristeleit	OHEAG	Personal	Amphista	Consultancy	Yes
Rebecca Kristeleit	OHEAG	Personal	Pharmamar	Consultancy and grant	Yes
Rebecca Kristeleit	OHEAG	Personal	Beigene	Grant	Yes
Rebecca Kristeleit	OHEAG	Personal	AstraZeneca	Consultancy	Yes
Rebecca Kristeleit	OHEAG	Personal	Clovis	Consultancy and grants	Yes
Rebecca Kristeleit	OHEAG	Personal	Roche	Consultancy	Yes
Rebecca Kristeleit	OHEAG	Personal	GSK	Consultancy	Yes
Rebecca Kristeleit	OHEAG	Personal	Eisai	Consultancy	No
Rebecca Kristeleit	OHEAG	Non-Personal	Various	Academic and Commercial Clinical Trial Programme with	Yes

				payments for trial work given to my Institution	
Reecha Sofat	PEAG	Personal	NIL	N/A	N/A
Reecha Sofat	PEAG	Non-Personal	NIL	N/A	N/A
Rhian Thomas-Turner	PMEAG	Personal	NIL	N/A	N/A
Rhian Thomas-Turner	PMEAG	Conferences /Scientific Meetings	AstraZenca, Sanofi	Sponsorship of conference - I was on the programme committee. Funding paid to EFGCP not to members of programme committee to pay for conference venue.	No
Rhian Thomas-Turner	PMEAG	Non-Personal	Sanofi	Team participation in delivering clinical trial	No
Rhian Thomas-Turner	PMEAG	Non-Personal	Astellia	Team participation in Skipper (gilteritinib) and nephrology study CKD study	No
Rhian Thomas-Turner	PMEAG	Non-Personal	Vertex	Team participation in delivering clinical trial	No
Rhian Thomas-Turner	PMEAG	Non-Personal	Noema Pharma	Team participation in delivering clinical trial	No
Rhian Thomas-Turner	PMEAG	Non-Personal	Sobi	AVAPED study – team participation in delivering clinical trial.	No

Rhian Thomas-Turner	PMEAG	Non-Personal	EspeRare	Team participation in the EDELife study.	No
Rhian Thomas-Turner	PMEAG	Non-Personal	MSD	Team participation in delivering clinical trial	No
Rhian Thomas-Turner	PMEAG	Non-Personal	X4 Pharmaceuticals	Team participation in delivering clinical trial	No
Rhian Thomas-Turner	PMEAG	Non-Personal	Takeda	Team participation in delivering clinical trial	No
Richard FitzGerald	PEAG	Personal	NIL	N/A	N/A
Richard FitzGerald	PEAG	Non-Personal	NIL	N/A	N/A
Richard Gilson	IEAG	Personal	NIL	N/A	N/A
Richard Gilson	IEAG	Non-Personal	Gilead Sciences	My department is a collaborating site in clinical trials sponsored by Gilead Sciences, who have provided research funds to the department (received by UCL and by Central and North West London NHS Foundation Trust)	Yes
Richard Gilson	IEAG	Non-Personal	GSK	My department is a collaborating site in clinical trials sponsored by GSK who have provided research funds to the department (received by UCL and by Central and North West London NHS Foundation Trust). I have been local principal	Yes

				and national chief investigator on multinational trials sponsored by GSK.	
Richard Gilson	IEAG	Non-Personal	Janssen	My department is a collaborating site in clinical trials sponsored by Janssen, who have provided research funds to the department (received by UCL and by Central and North West London NHS Foundation Trust)	Yes
Richard Gilson	IEAG	Non-Personal	Merck	My department is a collaborating site in clinical trials sponsored by Merck, who have provided research funds to the department (received by UCL and by Central and North West London NHS Foundation Trust)	Yes
Richard Gilson	IEAG	Non-Personal	Pfizer	My department is a collaborating site in clinical trials sponsored by Pfizer, who have provided research funds to the department (received by UCL and by Central and North West London NHS Foundation Trust)	Yes
Richard Gilson	IEAG	Non-Personal	ViiV	My department is a collaborating site in clinical trials sponsored by ViiV, who have provided research funds to the department (received by UCL and by Central and North London NHS Foundation Trust)	Yes

Richard Gilson	IEAG	Non-Personal	Procure Women Health Limited	Consultancy as Senior Scientific Advisor to Procure through a contract with UCL Consultants. All proceeds received by the UCL Institute for Global Health.	No
Member1	VEEWG	Personal	NIL	N/A	N/A
Member1	VEEWG	Non-Personal	NIL	N/A	N/A
Robert Andrews	HPMEWG	Personal	NIL	N/A	N/A
Robert Andrews	HPMEWG	Non-Personal	NIL	N/A	N/A
Robert Brown	VEEWG, HPMEWG	Personal	NIL	N/A	N/A
Robert Brown	VEEWG, HPMEWG	Non-Personal	NIL	N/A	N/A
Robert Lowe	CPSEAG, HPMEWG	Personal	NIL	N/A	N/A
Robert Lowe	CPSEAG, HPMEWG	Non-Personal	NIL	N/A	N/A
Robin Thorpe	CTBVEAG, HPMEWG	Personal	NIL	N/A	N/A
Robin Thorpe	CTBVEAG, HPMEWG	Non-Personal	NIL	N/A	N/A
Rod Mitchell	VEEWG	Personal	NIL	N/A	N/A

Rod Mitchell	VEEWG	Non-Personal	NIL	N/A	N/A
Rona Smith	CDRRA	Personal	Vifor Pharma	Honoraria	No
Rona Smith	CDRRA	Conferences /Scientific Meetings	GSK	European eGPA meeting: Expenses	No
Rona Smith	CDRRA	Non-Personal	GlaxoSmithKline	Clinical Study Grant	No
Rona Smith	CDRRA	Non-Personal	Union Therapeutics	Clinical Study Grant	No
Rubin Minhas	PMEAG	Personal	NIL	N/A	N/A
Rubin Minhas	PMEAG	Non-Personal	NIL	N/A	N/A
Rui Bebiano da Providencia e Costa	CHM	Personal	NIL	N/A	N/A
Rui Bebiano da Providencia e Costa	CHM	Non-Personal	NIL	N/A	N/A
Rupert Payne	PEAG	Personal	NIL	N/A	N/A
Rupert Payne	PEAG	Non-Personal	NIL	N/A	N/A

Rupert Payne	PEAG	Additional				I receive ongoing research funding from NIHR, Wellcome and MRC.
Rupert Payne	PEAG	Additional				I was consultant editor for the journal Prescriber (Wiley publishers) until end 2024; this journal carried advertising from the pharmaceutical industry, although I was not involved in this aspect of the journal.
Ruth Paulin	CPSEAG	Personal	NIL	N/A	N/A	
Ruth Paulin	CPSEAG	Non-Personal	NIL	N/A	N/A	
Sandosh Padmanabhan	CHM, CDRRA EAG	Personal	Kvatchii Limited	Founder shares	Yes	
Sandosh Padmanabhan	CHM, CDRRA EAG	Non-Personal	NIL	N/A	N/A	
Sarah Meredith	RWDEWG	Non-Personal	NIL	N/A	N/A	
Sarah Meredith	RWDEWG	Personal	NIL	N/A	N/A	
Sarah Wild	CDRRA EAG	Personal	NIL	N/A	N/A	
Sarah Wild	CDRRA EAG	Non-Personal	NIL	N/A	N/A	
Shahida Din	GRID EAG	Personal	Takeda	Speaker Fees	No	

Shahida Din	GRID EAG	Conferences /Scientific Meetings	Janssen	European Crohn's & Colitis Annual Meeting Stockholm: Flights, Accommodation, Symposium Registration Fees	No
Shahida Din	GRID EAG	Conferences /Scientific Meetings	Lilly	British Society of Gastroenterology annual meeting Birmingham: Registration, travel & accommodation support	No
Shahida Din	GRID EAG	Conferences /Scientific Meetings	Helmsley Charitable Trust	Helmsley Charitable Trust Annual Gut Cell Atlas meeting New York: Registration, travel & accommodation support	No
Shahida Din	GRID EAG	Conferences /Scientific Meetings	AbbVie	United European Gastroenterology Week annual meeting Vienna: Registration, travel & accommodation support	No
Shahida Din	GRID EAG	Conferences /Scientific Meetings	AbbVie	Women in IBD meeting London: Registration, travel & accommodation support	No
Shahida Din	GRID EAG	Non-Personal	Edinburgh & Lothian Health Foundations Award	Research funding	Yes
Shahida Din	GRID EAG	Non-Personal	Pathological Society of Great Britain & Northern Ireland	Research funding	Yes

Shahida Din	GRID EAG	Non-Personal	Helmsley Charitable Trust: Gut Cell Atlas Normal & Crohn's Disease	Research funding	Yes	
Shahida Din	GRID EAG	Non-Personal	Helmsley Charitable trust	Research funding	Yes	
Shahida Din	GRID EAG	Non-Personal	Helmsley Charitable Trust	Research funding	Yes	
Shahida Din	GRID EAG	Non-Personal	AbbVie	Research Fee to Unit Research and Development Fund as PI	No	
Shahida Din	GRID EAG	Additional				<p>Leadership Roles</p> <p>1. British Society of Gastroenterology 2019- to date Inflammatory Bowel Disease Section Committee Member</p> <p>2. Royal College of Physicians of Edinburgh 2020 to date Gastroenterology Specialty Advisor</p> <p>3. Scottish Government 2021 to date Lead for Inflammatory Bowel Disease - Cancer Surveillance</p>
Shahida Din	GRID EAG	Additional				<p>Collaborator for Clinical Trial. Funder: John Moulton Foundation</p> <p>Sponsor: NHS Lothian /University of Edinburgh</p>

Shahida Din	GRID EAG	Additional				Principal (or Sub) Investigator for Clinical Trial: Current Trials Role Sub-PI Funder: Helmsley Charitable Trust Sponsor: King's College London
Shahida Din	GRID EAG	Additional				Role PI Funder AbbVie Sponsor AbbVie
Shahida Din	GRID EAG	Additional				Role Sub-PI Funder NIHR -HTA Sponsor: University of Birmingham
Shirley Price	PMEAG, HPMEWG, VEEWG	Personal	NIL	N/A	N/A	
Shirley Price	PMEAG, HPMEWG, VEEWG	Non-Personal	GSK	Annual donation to the British Toxicology Society of which I am a Trustee for support of education and training activities. The BTS is a charity and its Charity Registration No: 286197	Yes	Please note I hold an Honorary Fellowships from the British Toxicology Society and the UK Health Security Agency.
Shirley Price	PMEAG, HPMEWG, VEEWG	Non-Personal	AstraZeneca	Annual donation to the British Toxicology Society of which I am a Trustee for support of education and training activities. The BTS is a charity and its Charity Registration No: 286197	Yes	Please note I hold an Honorary Fellowships from the British Toxicology Society and the UK Health Security Agency.

Shirley Price	PMEAG, HPMEWG, VEEWG	Non-Personal	Apconix	Donation to the British Toxicology Society of which I am a Trustee for general support of the 2024 Annual Congress. The BTS is a charity and its Charity Registration No: 286197	No	Please note I hold an Honorary Fellowships from the British Toxicology Society and the UK Health Security Agency.
Shuaib Nasser	CDRRA EAG	Personal	Galderma	Consultancy	No	
Shuaib Nasser	CDRRA EAG	Personal	ALK	Consultancy and lecture	No	
Shuaib Nasser	CDRRA EAG	Non-Personal	NIL	N/A	N/A	
Simon Drysdale	PMEAG	Personal	NIL	N/A	N/A	
Simon Drysdale	PMEAG	Non-Personal	Janssen, AstraZeneca, Pfizer, Moderna, Valneva, GSK, MSD, iLiAD, MundiPharma and Sanofi	Consultancy and/or investigator roles (all fees paid to his institution)	Yes	
Simon Drysdale	PMEAG	Non-Personal	MSD	Investigator Initiated research grants (all funds paid to my institution)	Yes	
Simon Drysdale	PMEAG	Additional				Member of the UK Department of Health and Social Care's (DHSC) Joint Committee on Vaccination and Immunisation (JCVI) RSV subcommittee.
Siow-Ming Lee	OHEAG	Personal	NIL	N/A	N/A	

Siow-Ming Lee	OHEAG	Conferences /Scientific Meetings	Roche	ESMO: Conference attendance, Transport and Registration Fees	No	
Siow-Ming Lee	OHEAG	Non-Personal	NIL	N/A	N/A	
Member3	VIEWG	Personal	NIL	N/A	N/A	
Member3	VIEWG	Non-Personal	NIL	N/A	N/A	
Member3	VIEWG	Additional				I have an interest in the safe prescribing of valproate and developed and led an audit on the topic which has been published.
Stella O'Brien	MWHEAG	Personal	NIL	N/A	N/A	
Stella O'Brien	MWHEAG	Non-Personal	NIL	N/A	N/A	
Stella O'Brien	MWHEAG	Additional				Public voice member of CRUK (Cancer Research UK) Prevention, Early Detection & Diagnosis Patient and Public Panel and International Alliance for Cancer Early Detection (ACED) Patient and Public Panel. Standard NIHR public involvement honorarium for decision-making activities.
Stella O'Brien	MWHEAG	Additional				Public member of Surface Sampling Guidelines Working Group of HIS (Healthcare

			Infection Society). Standard NIHR public involvement honorarium
Stella O'Brien	MWHEAG	Additional	Voluntary citizen member of HTAi (Health Technology Appraisal International), no remuneration
Stella O'Brien	MWHEAG	Additional	Graduate of their Patient Research Advocacy program of IASLC
Stella O'Brien	MWHEAG	Additional	Public member for the MHRA's IDAP panel
Stella O'Brien	MWHEAG	Additional	Public member of Quality Committee at NHS England
Stella O'Brien	MWHEAG	Additional	Lay member of Technical Appraisal Committee and Expert Panels for the Diagnosis and Management of COVID-19 at NICE. Public member for NIHR. Chair Engagement and Involvement Committee Standard NIHR public involvement honorarium.
Stella O'Brien	MWHEAG	Additional	Public member of Public Advisory Board at the Our Future Health
Stella O'Brien	MWHEAG	Additional	Chair of Engagement and Involvement Committee at THIS (The Health Improvement Studies) Institute Cambridge. Standard NIHR public involvement honorarium.

Steven Cunningham	CHM, PMEAG	Personal	NIL	N/A	N/A
Steven Cunningham	CHM, PMEAG	Non-Personal	Gilead	Bronchiolitis RSV antiviral trial development. Employer fees paid to University of Edinburgh.	No
Steven Cunningham	CHM, PMEAG	Non-Personal	ArkBiosciences	Bronchiolitis RSV antiviral trial development. Employer fees paid to University of Edinburgh.	No
Steven Cunningham	CHM, PMEAG	Non-Personal	Inhalon	Bronchiolitis RSV antiviral trial development. Employer fees paid to University of Edinburgh.	No
Steven Cunningham	CHM, PMEAG	Non-Personal	Pfizer	Bronchiolitis RSV antiviral trial development. Employer fees paid to University of Edinburgh.	No
Steven Cunningham	CHM, PMEAG	Non-Personal	Boehringer Ingelheim	Trial steering committee with employer fees paid to the University of Edinburgh.	No
Steven Cunningham	CHM, PMEAG	Additional			
Stuart H Ralston	MWHEAG	Personal	NIL	N/A	N/A
Stuart H Ralston	MWHEAG	Non-Personal	Abbvie	Support for scientific meeting	No

01.24-03.24 I was a member of an EU IMI research consortium (RESCEU to 9/22 now PROMISE) which had Oxford University and Imperial College as academic partners.

Stuart H Ralston	MWHEAG	Non-Personal	Accord	Support for scientific meeting	No
Stuart H Ralston	MWHEAG	Non-Personal	Amgen	Support for scientific meeting	No
Stuart H Ralston	MWHEAG	Non-Personal	CSL Vifor	Support for scientific meeting	No
Stuart H Ralston	MWHEAG	Non-Personal	Jannsen	Support for scientific meeting	No
Stuart H Ralston	MWHEAG	Non-Personal	Eli-Lilly	Support for scientific meeting	No
Stuart H Ralston	MWHEAG	Non-Personal	Novartis	Support for scientific meeting	No
Stuart H Ralston	MWHEAG	Non-Personal	Thornton and Ross	Support for scientific meeting	No
Stuart H Ralston	MWHEAG	Non-Personal	UCB	Support for scientific meeting	No
Stuart H Ralston	MWHEAG	Non-Personal	UCB	Consultancy to Institution	No
Stuart H Ralston	MWHEAG	Non-Personal	Angitia	Consultancy to Institution	No
Stuart H Ralston	MWHEAG	Non-Personal	Kyowa Kirin	Support for recruiting patients into a clinical registry study	No
Stuart H Ralston	MWHEAG	Non-Personal	Eli-Lilly	Donation of Teriparatide for a clinical trial	No

Stuart H Ralston	MWHEAG	Additional				External examiner for Oxford University Clinical Trials MSc course, Jan 2024 - Nov 2024
Susan Hunneyball	PEAG, ARMEWG	Personal	NIL	N/A	N/A	
Susan Hunneyball	PEAG, ARMEWG	Non-Personal	NIL	N/A	N/A	
Susan Hunneyball	PEAG, ARMEWG	Additional				I write articles published in the Chemist and Druggist magazine, a trade magazine for pharmacists but receive no payment for those articles. The information referred to is in the public domain. I make it clear that these are my personal views and reflections and references all sources of information used.
Susannah Walsh	CPSEAG	Personal	Better Vision Solutions	Consultancy and licence agreement for technology. Named on patents.	Yes	
Susannah Walsh	CPSEAG	Personal	Chemical Biological Center of Combat Capabilities Development Command and Defence Threat Reduction Agency	Research collaboration and MTA . Named on DMU Patents associated with work.	Yes	
Susannah Walsh	CPSEAG	Personal	Techfest	Director	Yes	

Susannah Walsh	CPSEAG	Personal	University of Wolverhampton	External examiner (educational consultancy)	Yes	
Susannah Walsh	CPSEAG	Personal	Kingston University	External examiner (educational consultancy)	No	
Susannah Walsh	CPSEAG	Personal	Safer Disinfectant Network	I have attended some online meetings involving academics and disinfection companies run by the Safer Disinfectant Network. I have no personal links to the companies who are signed up to their charter (to promote best practice and support public health in the workplace) beyond those detailed above.	Yes	I have not attended a meeting for more than a year and am not sure if this organisation is still active.
Susannah Walsh	CPSEAG	Non-Personal	NIL	N/A	N/A	
Sylvia Kama-Kieghe	MWHEAG	Personal	NIL	N/A	N/A	
Sylvia Kama-Kieghe	MWHEAG	Conferences /Scientific Meetings	Theramex	Menopause Mentoring Programme/Course: Free course 3 x 1-hour sessions	No	
Sylvia Kama-Kieghe	MWHEAG	Non-Personal	NIL	N/A	N/A	
Tejal Mitchell	VIEWG	Personal	GW Pharma	Honorarium for participating in educational symposium (non-promotional)	No	

Tejal Mitchell	VIEWG	Conferences /Scientific Meetings	UCB Pharma	DCEE educational event: Expenses (accommodation, meeting costs)	No
Tejal Mitchell	VIEWG	Non-Personal	UCB Pharma	Sponsorship of Seizure Semiology and EEG course 2024	No
Tejal Mitchell	VIEWG	Non-Personal	Angelini Pharma	Sponsorship of Seizure Semiology and EEG course 2024	No
Tejal Mitchell	VIEWG	Non-Personal	Eisai	Sponsorship of Seizure Semiology and EEG course 2024	No
Tejal Mitchell	VIEWG	Non-Personal	Micromed	Sponsorship of Seizure Semiology and EEG course 2024	No
Theresa McDonagh	CDRRA EAG	Personal	Boehringer Ingelheim	Fees for speaking / chairing at meetings	No
Theresa McDonagh	CDRRA EAG	Non-Personal	NIL	N/A	N/A
Tom Clutton-Brock	HPMEWG	Personal	NIL	N/A	N/A
Tom Clutton-Brock	HPMEWG	Non-Personal	NIL	N/A	N/A
Tom Clutton-Brock	HPMEWG	Additional			

Director, Medical Devices
Testing and Evaluation Centre
Clinical Director, NIHR
HealthTech Research Centre
in Devices, Digital and
Robotics
Chair, NICE Interventional
Procedures Advisory

Committee
Associate Medical Director,
University Hospitals
Birmingham NHS Foundation
Trust
Professor of Anaesthesia &
Intensive Care Medicine,
University of Birmingham,
Chair of the interim Devices
Committee, MHRA

Vanessa Raymont	CHM, VIEWG, ARMEWG	Personal	NIL	N/A	N/A
Vanessa Raymont	CHM, VIEWG, ARMEWG	Conferences /Scientific Meetings	Eisai	Promotional Meeting Optimising the Treatment of Early Alzheimer's Disease: A Collaborative Approach: Travel expenses to meeting	No
Vanessa Raymont	CHM, VIEWG, ARMEWG	Conferences /Scientific Meetings	Eisai	Podcast: Service Optimisation: Evolving Patient Pathways in AD	No
Vanessa Raymont	CHM, VIEWG, ARMEWG	Conferences /Scientific Meetings	IQVIA and Eli Lilly	Travel expenses to meeting	No
Vanessa Raymont	CHM, VIEWG, ARMEWG	Non-Personal	Janssen	Offer of potential funding for research study mainly funded by Medical Research Council grant for which I am Chief Investigator	No
Vanessa Raymont	CHM, VIEWG, ARMEWG	Non-Personal	Lilly	Staffing costs provided via a Collaborative Working Agreement to do a pilot project to expand	No

CSF testing in NHS memory clinics for which I am Chief Investigator					
Vanessa Raymont	CHM, VIEWG, ARMEWG	Additional			I have acted as a local site Principal Investigator for commercial clinical trials for the following companies: ACI Biogen J and J AriBio
Wajid Hussain	CDRRA EAG	Personal	NIL	N/A	N/A
Wajid Hussain	CDRRA EAG	Non-Personal	NIL	N/A	N/A
Waqar Rashid	NPPEAG	Personal	NIL	N/A	N/A
Waqar Rashid	NPPEAG	Non-Personal	NIL	N/A	N/A
William Herrington	CDRRA	Personal	NIL	N/A	N/A
William Herrington	CDRRA	Non-Personal	Eli Lilly	Grant to the University of Oxford	Yes
William Herrington	CDRRA	Non-Personal	Boehringer Ingelheim	Grant to the University of Oxford	Yes
Member5	VIEWG	Personal	NHS England	Salary	Yes
Member5	VIEWG	Non-Personal	NIL	N/A	N/A

William John Watkins	PMEAG	Personal	NIL	N/A	N/A
William John Watkins	PMEAG	Non-Personal	NIL	N/A	N/A
Yvonne Perrie	CHM, CPSEAG, HPMEWG	Personal	NIL	N/A	N/A
Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	CURIA	Knowledge exchange research contracts from company to University of Strathclyde and joint PhD funding.	No
Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	Imperial College London	Research Collaborator: VaxHub Grant to University of Strathclyde.	No
Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	Microfluidics Inc	Equipment loan to University of Strathclyde and in-kind research support (consumables).	No
Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	Avanti polar lipids/CRODA	BBSRC Icase PhD studentship grant to University of Strathclyde	No
Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	AstraZeneca	PhD studentships including Icase.	No
Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	Defence Threat Reduction Agency DTRA (administered by DSTL)	Research Grant to University of Strathclyde	No

Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	Janssen Pharmaceutica	Research Grant to University of Strathclyde	No
Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	Target Healthcare	Knowledge Transfer Partnership research Grant to University of Strathclyde	No
Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	Takeda / Millenium Pharmaceuticals	Knowledge exchange research contracts from company to University of Strathclyde	No
Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	LEON Nano Drugs GmbH	Knowledge exchange research contracts from company to University of Strathclyde	No
Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	Precision Nanomedicines Inc	Knowledge exchange research contracts from company to University of Strathclyde and joint PhD funding. Equipment loan to University of Strathclyde to support project.	No
Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	NOF CORPORATION	Knowledge exchange research contracts from company to University of Strathclyde	No
Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	Micropore Technologies Ltd	Knowledge exchange research contracts from company to University of Strathclyde and joint PhD funding. Equipment loan to University of Strathclyde. Innovate UK grant.	No

Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	pHion	Innovate UK grant to University of Strathclyde	No
Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	ABITEC	Joint PhD funding	No
Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	Centre for process Innovation Ltd	Research Grant to University of Strathclyde	No
Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	Micropore ABITEC AstraZeneca Colorcon Croda	PhD CDT Training programme where I am Co-I. CMAC CEDAR	No
Yvonne Perrie	CHM, CPSEAG, HPMEWG	Non-Personal	Pfizer Sanofi Chiesi UCB Takeda Lilly Roche	Whilst not directly linked to my Nanomedicines theme in the PhD CDT programme, other companies are linked to the grant.	No
Yvonne Perrie	CHM, CPSEAG, HPMEWG	Additional			

I am Head of Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS). We are an internationally leading technological University and as such we work with many companies across the dept, faculty and University. We also work with Health care providers including a wide range of NHS trusts and pharmacies through both research and education.

Yvonne Perrie

CHM, CPSEAG,
HPMEWG

Additional

I am Head of Strathclyde
Institute of Pharmacy and
Biomedical Sciences (SIPBS).
We are an internationally
leading technological
University and as such we
work with many companies
across the dept, faculty and
University. We also work with
Health care providers
including a wide range of NHS
trusts and pharmacies through
both research and education.

Contact information about these reports:

Medicines and Healthcare products Regulatory Agency
Customer Services
10 South Colonnade
Canary Wharf
London E14 4PU

Tel: 020 3080 6000

E-mail: info@mhra.gov.uk

© Crown copyright 2025

Published by the Medicine and Healthcare products Regulatory Agency

ISBN 978-1-8384147-4-0

Guidance on reproducing and re-using MHRA Crown copyright material can be found on our website at:
<http://www.nationalarchives.gov.uk/information-management/re-using-public-sector-information/copyright-and-re-use/crown-copyright/>